moxifloxacin has been researched along with levofloxacin in 442 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 4,346 | 581 | 2,209 |
| Protein | Taxonomy | moxifloxacin (IC50) | levofloxacin (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 7.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (0.90) | 18.2507 |
| 2000's | 216 (48.87) | 29.6817 |
| 2010's | 177 (40.05) | 24.3611 |
| 2020's | 45 (10.18) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Keserü, GM | 1 |
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Baroni, M; Cecchetti, V; Cianchetta, G; Cruciani, G; Mannhold, R | 1 |
| Inagaki, H; Takahashi, H; Takemura, M | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Choi, TY; Pai, H; Seo, MR | 1 |
| Arpin, C; Ba, BB; Caignard, DH; Forfar-Bares, I; Grellet, J; Guillon, J; Jarry, C; Moreau, S; Quentin, C; Vidaillac, C | 1 |
| Appelbaum, PC; Credito, KL; DeWasse, B; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Klugman, KP; Levin, BR; McGee, L; Rozen, DE | 1 |
| Black, JA; Hanson, ND; Hong, SG; Hossain, A; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Nelson, DM; Ou, Y; Pais, GC; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
| Campos, J; García-Cobos, S; Pérez-Vázquez, M; Román, F | 1 |
| Kaatz, GW; LaPlante, KL; Lodise, TP; Rybak, MJ; Tsuji, B | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Cottagnoud, M; Cottagnoud, P; Schaffner, T; Stucki, A; Winkelmann, V | 1 |
| Cano, ME; García, I; Martínez-Martínez, L; Pascual, A; Rodríguez-Martínez, JM; Velasco, C | 1 |
| Courvalin, P; Galimand, M; Périchon, B | 1 |
| Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH | 1 |
| Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP | 1 |
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Adams, DA; Donskey, CJ; Riggs, MM | 1 |
| Ardanuy, C; Bouza, E; Calatayud, L; Cercenado, E; Fenoll, A; Liñares, J; Martín, R; Pallares, R | 1 |
| Arsène, S; Leclercq, R | 1 |
| Homma, T; Hori, T; Sugimori, G; Yamano, Y | 1 |
| Morgan-Linnell, SK; Zechiedrich, L | 1 |
| Fukushima, K; Higashiyama, Y; Hirakata, Y; Kohno, S; Kohno, Y; Miyazaki, Y; Ohno, H; Yanagihara, K | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Appelbaum, PC; Clark, CL; Ednie, LM; Kosowska-Shick, K | 1 |
| Calvet, L; Devine, R; Dubreuil, L; Jean-Pierre, H; Jumas-Bilak, E; Marchandin, H; Mercier, G; Morio, F | 1 |
| Andres, P; Centrón, D; Galas, M; Guerriero, L; Petroni, A; Quiroga, C; Quiroga, MP; Soler Bistué, AJ; Tokumoto, M; Tolmasky, ME; Vargas, LJ; Zorreguieta, A | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K | 1 |
| Boom, WH; Dietze, R; Hadad, DJ; Johnson, JL; Molino, LP; Palaci, M; Peloquin, CA | 1 |
| Brémont, S; Courvalin, P; Damier-Piolle, L; Lambert, T; Magnet, S | 1 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
| Ho, YR; Hung, KH; Janapatla, RP; Wu, CW; Wu, HM; Wu, JJ; Yan, JJ | 1 |
| Beckius, ML; Fraser, SL; Galloway, RL; Griffith, ME; Hospenthal, DR; Mende, K; Miller, RS; Murray, CK; Pimentel, G; Ressner, RA | 1 |
| Chang, KY; Ho, YH; Hsieh, YC; Hsueh, PR; Huang, LM; Huang, YC; Lin, HC | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Hsueh, PR; Huang, YT; Liao, CH; Lin, HY; Liu, CY; Yen, LC | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Hiramatsu, K; Kikuchi, K; Ohtsuka, M; Ono, Y; Sasaki, T; Shimizu, K; Takahashi, N | 1 |
| Crabb, DM; Duffy, LB; Waites, KB | 1 |
| Baines, SD; Freeman, J; O'Connor, R; Saxton, K; Wilcox, MH | 1 |
| Bremont, S; Charavay, F; Courvalin, P; Goarant, C; Le Hello, S; O'Connor, O; Page, S; Vernel-Pauillac, F | 1 |
| Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Wehmeier, C | 1 |
| Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Barbanti, F; Barbut, F; Louie, T; Mastrantonio, P; Spigaglia, P | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hirakata, Y; Imamura, Y; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Seki, M; Sugahara, K; Yamamoto, K; Yamamoto, Y; Yanagihara, K | 1 |
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Caddick, JM; Gunell, M; Hakanen, AJ; Huovinen, P; Jalava, J; Kotilainen, P; Lilly, AJ; Piddock, LJ; Siitonen, A; Webber, MA | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS | 1 |
| Adam, HJ; Hoban, DJ; King, CR; Laing, NM; Lulashnyk, B; Zhanel, GG | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Larruskain, J; Montes, M; Orden, B; Perez-Trallero, E; Tamayo, E | 1 |
| Brillault, J; Couet, W; De Castro, WV | 1 |
| Martínez, JL; Sánchez, MB | 1 |
| Appelbaum, PC; Beachel, L; Clark, C; Dewasse, B; Kosowska-Shick, KM; McGhee, P; Nagai, K | 1 |
| Appelbaum, PC; Credito, K; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chen, HC; King, CH; Lai, JF; Lauderdale, TL; Shiau, YR | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Amsler, KM; Bush, K; Foleno, BD; He, W; Lynch, AS; Macielag, MJ; Morrow, BJ | 1 |
| Bajaksouzian, S; Biek, D; Critchley, IA; Good, CE; Jacobs, MR; Jones, RN; Sader, HS; Windau, AR | 1 |
| Ardanuy, C; Brito-Avô, A; Gonçalo-Marques, J; Liñares, J; Morais, A; Pires, R; Rolo, D; Santos-Sanches, I | 1 |
| Disratthakit, A; Doi, N | 1 |
| Barber, M; Eberly, LE; Feeney, LA; Miller, GH; Summers, A; Wortmann, G; Zapor, MJ | 1 |
| Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA | 1 |
| Al-Trawneh, SA; Alfieri, RR; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Kamal, MR; Petronini, PG; Vicini, P; Zahra, JA; Zani, F | 1 |
| Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ | 1 |
| Drlica, K; German, N; Kerns, RJ; Malik, M; Marks, KR; Schwanz, HA | 1 |
| Hamprecht, A; Higgins, PG; Schneiders, T; Seifert, H | 1 |
| Briales, A; Díaz de Alba, P; Domínguez-Herrera, J; Pachón, J; Pascual, A; Rodríguez-Martínez, JM; Velasco, C | 1 |
| Bradbury, BJ; Deshpande, M; Hashimoto, A; Kim, HY; Lucien, E; Nelson, DM; Pais, GC; Podos, SD; Pucci, MJ; Thanassi, JA; Wang, Q; Wiles, JA | 1 |
| Al-Taweel, SA; Al-Trawneh, SA; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Vicini, P; Zahra, JA; Zani, F | 1 |
| Chai, Y; Guo, HY; Li, SJ; Liu, ML; Wang, B; Wang, JX; Zhang, YB | 1 |
| Cao, J; Feng, L; Guo, H; Li, S; Liu, M; Lv, K; Wang, S; You, X; Zhao, J | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Guo, H; Huang, J; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, J; Wang, M | 1 |
| Bao, Y; Huang, X; Lan, S; Wang, T; Zhang, X; Zhu, S | 1 |
| Huang, J; Li, L; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, C; Wang, M; Zhang, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Feng, L; Huang, J; Li, X; Liu, M; Lu, Y; Wang, B; Wang, M; Wu, Z; Yang, Y; Zhang, J | 1 |
| Lynch, AS; Ma, Z | 1 |
| Cvijetić, IN; Drakulić, BJ; Ernesto de Resende, P; Gibbons, S; Juranić, IO; Stapleton, P; Verbić, TŽ; Zloh, M | 1 |
| Almstead, NG; Arnold, MA; Baird, J; Branstrom, AA; Chen, G; Dumble, M; Gerasyuto, AI; Karp, GM; Narasimhan, J; Peddi, S; Prasad, JVN; Sheedy, J; Smith, S; Wang, J; Weetall, M; Woll, MG; Zhang, N; Zhang, X | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Nagamochi, M; Odagiri, T; Takahashi, H | 1 |
| Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W | 1 |
| Berry, L; Brizuela, M; Domalaon, R; Schweizer, F; Zhanel, GG | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Betson, M; Bingham, M; Doyle, P; Hallworth, S; Harvey, R; Huxley, A; Kirk, R; Moat, J; Nelson, G; Pesnot, T; Tait, M | 1 |
| Bhagwat, S; Bhawsar, S; Deshpande, P; Joshi, S; Patel, M; Yeole, R | 1 |
| Bauernfeind, A | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Barry, AL; Brown, SD; Fuchs, PC | 1 |
| Brisse, S; Fluit, AC; Köhrer, K; Martin, N; Milatovic, D; Scheuring, S; Schmitz, FJ; Verhoef, J | 1 |
| Bjarnason, J; Blondeau, JM; Laskowski, R; Stewart, C | 1 |
| Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
| Coleman, EJ; Mandell, GL | 1 |
| Firsov, AA; Kononenko, OV; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH | 1 |
| Doern, GV; Ernst, EJ; Klepser, ME; Petzold, CR; Rhomberg, P | 1 |
| Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M | 1 |
| Hedges, AJ; MacGowan, AP; Sunderland, J; Tobin, CM; White, LO | 1 |
| Lister, PD | 1 |
| Cheon, SH; Dietze, R; Ellner, JJ; Hise, AG; Landen, K; Palaci, M; Phillips, M; Ribeiro, FC; Song, HY; Vinhas, S; Wallis, RS | 1 |
| Climent, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Black, J; Chartrand, SA; Moland, ES; Thomson, KS | 1 |
| Johnson, AP; Livermore, DM; Warner, M | 1 |
| Lister, PD; Sanders, CC | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Appelbaum, PC; Davies, T; Edlund, C; El Amin, N; Oh, H | 1 |
| Adrián, F; del Campo, R; García, C; Gómez-Lus, P; Gómez-Lus, R; Rubio, MC; Sánchez, S | 1 |
| Georgopoulos, A; Graninger, W; Grisold, A; Mueller-Uri, P; Presterl, E | 1 |
| Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V | 1 |
| Rossi, C; Sternon, J | 1 |
| Piddock, LJ; Ricci, V | 1 |
| Arias-Puente, A; Carrasco-Font, C; Fresnadillo-Martinez, MJ; García-Sáenz, MC | 1 |
| Barrett, JF; Chaniewski, S; Frosco, M; Hooper, DC; Lawrence, LE; Ryan, B; Yang, H | 1 |
| Frothingham, R | 2 |
| Drlica, K; Li, X; Zhao, X | 1 |
| Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I | 1 |
| Karenchak, LM; Kowalski, RP; Mather, R; Romanowski, EG | 1 |
| Appelbaum, PC; Bozdogan, B; Clark, CL; Davies, TA; Dewasse, B; Jacobs, MR; Nagai, K | 1 |
| Appelbaum, PC; Bozdogan, B; Browne, FA; Clark, C; Dewasse, BE; Jacobs, MR | 1 |
| Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH | 2 |
| Bercion, R; Carricajo, A; Celard, M; Chomarat, M; Croizé, J; Delubac, F; Fèvre, D; Frédénucci, I; Fuhrmann, C; Helfre, M; Lelièvre, H; Letouzey, MN; Mandjee, A; Marthelet, P; Meley, R; Perrier-Gros-Claude, JD; Ros, A; Roure, C; Smati, S; Thierry, J; Tous, J | 1 |
| López, M; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Cheong, HJ; Choo, YS; Kang, MW; Kim, WJ; Kim, YS; Lee, KW; Park, YJ; Woo, JH; Yong, DE | 1 |
| Ariano, RE; Harding, GK; Iacovides, H; Sun, S; Zelenitsky, SA | 1 |
| Abels, R; Chien, S; Goodman, DB; Hunt, TL; Natarajan, J; Noel, GJ | 1 |
| Häfner, H; Klik, S; Lemmen, SW; Lütticken, R; Zolldann, D | 1 |
| López, M; Rodriguez Díaz, JC; Royo, G; Ruiz, M | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Ameyama, S; Shinmura, Y; Takahata, M | 1 |
| Aguilar, L; Garcia-Mendez, E; Jiménez De Anta, MT; Marco, F; Mensa, J; Ruiz, J; Sierra, JM; Vila, J | 1 |
| Allen, GP; Kaatz, GW; Rybak, MJ | 1 |
| Bosso, JA; Enzweiler, KA; White, RL | 1 |
| Carter, O; Counts, C; Dodson, S; Lody, C; Madhusudhan, KT; Ojha, N | 1 |
| Piddock, L; Ricci, V | 1 |
| Dhaliwal, DK; Gordon, YJ; Karenchak, LM; Kowalski, RP; Mah, FS; Ritterband, DC; Romanowski, EG | 1 |
| Leggett, J; Saravolatz, LD | 1 |
| Garrison, MW; Madaras-Kelly, KJ; Schimmels, JA | 1 |
| Aracil, B; Campos, J; Cantón, R; Pérez-Vázquez, M; Román, F | 1 |
| Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C | 1 |
| Hwang, DG | 1 |
| Elliott, MA; Patel, R; Prabhu, RM | 1 |
| Florea, NR; Nicolau, DP; Nightingale, CH; Tessier, PR; Zhang, C | 1 |
| Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S | 1 |
| Bergoin, E; Charles, PE; Chavanet, P; Croisier, D; Etienne, M; Lequeu, C; Piroth, L; Portier, H | 1 |
| Martinez, FJ | 1 |
| Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA; Traidej, M | 1 |
| Burkhardt, O; Köhnlein, T; Pap, T; Welte, T | 1 |
| Chuah, SK; Gollapudi, S; Thadepalli, H | 1 |
| Bernabo, J; Eiguchi, K; Farinati, A; Miller, RD; Molestina, RE; Ramirez, JA; Summersgill, JT; Uriarte, SM | 1 |
| Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Schooley, S; Stein, GE | 1 |
| Bast, DJ; Bell, D; Chen, X; de Azavedo, JC; Dresser, L; Low, DE; Mandell, LA; Saskin, R; Yue, M | 1 |
| Greisman, J; Hoban, CJ; Hoban, DJ; Noreddin, AM; Schurek, KN; Siemens, CG; Smith, HJ; Zhanel, GG | 1 |
| Ba, BB; Grellet, J; Nguyen, HA; Quentin, C; Saux, MC | 1 |
| Bouros, DE; Kottakis, I; Liapakis, IE; Light, RW; Pitiakoudis, MS; Simopoulos, CE; Tsatsakis, AM; Tzatzarakis, MN; Ypsilantis, P | 1 |
| Alou, L; Cafini, F; Prieto, J; Sevillano, D; Valero, E | 1 |
| Drlica, K; Li, X; Mariano, N; Rahal, JJ; Urban, CM | 1 |
| García-Tapia, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Hoepelman, I | 1 |
| Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D | 1 |
| Hermsen, ED; Hovde, LB; Rodvold, KA; Rotschafer, JC; Sprandel, KA | 1 |
| Barcia-Macay, M; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC | 1 |
| Michot, JM; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| De Vecchi, E; Drago, L; Legnani, D; Nicola, L; Prenna, M; Ripa, S | 1 |
| Baltch, AL; Bopp, LH; Michelsen, PB; Ritz, WJ; Smith, RP | 1 |
| Anon, JB | 1 |
| Cabeza, JG; Hernandez, J; Llagostera, M; Mensa, J; Montero, T; Ruiz Chaler, M; Sierra, JM; Vila, J | 1 |
| Almela, M; Jurado, A; Marco, F; Mensa, J; Ortega, M; Soriano, A | 1 |
| Abelson, MB; Shapiro, A; Torkildsen, G; Wagner, RS | 1 |
| Jung, HC; Kim, JM; Kim, JS; Kim, N; Song, IS | 1 |
| Marchese, A; Roveta, S; Schito, AM; Schito, GC | 1 |
| Alegakis, D; Falagas, M; Falagas, ME; Gikas, AH; Kofteridis, DP; Mantadakis, E; Maraki, S; Papadakis, JA; Samonis, G | 1 |
| Anzueto, A; Choudhri, S; Dimarco, JP; Morganroth, J; Niederman, MS | 1 |
| Anzueto, A; Choudhri, SH; Heyder, A; Niederman, MS; Pearle, J; Restrepo, MI | 1 |
| Caballero, AR; Dajcs, JJ; Johnston, KH; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Friedman, HS; Keating, KN; Perfetto, EM | 1 |
| Cox, CD; Meyerrose, GE; Peeters, MJ; Seifert, CF; Tsikouris, JP | 1 |
| Amábile-Cuevas, CF; Ariza, H; Caballero, A; García-Calderón, A; Hernández-Oliva, G; Jardim, JR; Urueta-Robledo, J; Vivar-Orozco, R | 1 |
| Dalhoff, A; Schubert, S; Stass, H; Ullmann, U | 1 |
| Alou, L; del Carmen Ponte, M; Gracia, M; Huelves, L; López-Casla, MT; Martínez-Marín, C; Prieto, J; Sevillano, D; Soriano, F | 1 |
| Siewert, S | 1 |
| Kamel, AG; Lim, VK; Norazah, A; Rohani, MY | 1 |
| Lück, PC; Steinert, M | 1 |
| Ackermann, T; Bertram, N; Paar, WD; Sauerbruch, T; Schulte, S | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Bayar, B; Bozkurt, A; Dinçel, A; Duman, S; Kaya, E; Oflu, Y; Yağci, R; Yağci, S | 1 |
| Aydemir, S; Cilli, F; Tunger, A | 1 |
| Boom, WH; Charlebois, ED; Daley, CL; Debanne, SM; Dietze, R; Eisenach, KD; Hadad, DJ; Jankus, DD; Johnson, JL; Maciel, E; Palaci, M; Peloquin, CA | 1 |
| Aguilar, L; Alou, L; Cafini, F; Echeverría, O; Giménez, MJ; Pérez-Trallero, E; Prieto, J; Sevillano, D | 1 |
| Deryke, CA; Du, X; Nicolau, DP | 1 |
| Bommer, M; Döhner, H; Kern, P; Kern, WV; Marre, R; Reuter, S; Sigge, A; von Baum, H | 1 |
| Krause, R; Laferl, H; Széll, M; Wenisch, C | 1 |
| Cars, O; Odenholt, I | 1 |
| Dhalla, IA; Juurlink, DN; Kopp, A; Mamdani, MM; Rochon, PA; Simor, AE | 1 |
| Asbell, PA; Bottone, EJ; Epstein, SP | 1 |
| Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, C | 1 |
| Black, JA; Hanson, ND; Smith Moland, E; Thomson, KS; Wickman, PA | 1 |
| Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG | 1 |
| Aloisi, GG; Amelia, M; Barbafina, A; Canton, M; Dall'Acqua, F; Elisei, F; Facciolo, L; Latterini, L; Vedaldi, D; Viola, G | 1 |
| Rodríguez, JC; Royo, G; Ruiz, M; Sirvent, E | 1 |
| Biller, P; Brennan, M; Killgore, G; Lind, L; McDonald, LC; Shank, B; Thompson, A; Tkatch, L | 1 |
| Gidoh, M | 1 |
| DeRyke, AC; Fan, HW; Lee, SY; Nicolau, DP; Sutherland, C | 1 |
| Bower, KS; Colyer, MH; Dick, JS; Haller, JA; Ward, TP; Weber, ED; Weichel, ED | 1 |
| Dubois, V; Grellet, J; Nguyen, HA; Quentin, C; Saux, MC | 1 |
| Breithardt, G; Cakir, Y; Eckardt, L; Engelen, MA; Haverkamp, W; Hilker, E; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Stypmann, J | 1 |
| Blondeau, JM; Borsos, S; Hesje, CK | 1 |
| Hart, D; Weinstein, MP | 1 |
| Choi, EC; Choi, JS; Joo, CK; Kim, SY; Lim, JA | 1 |
| Czock, D; de Groot, K; Fliser, D; Hafer, C; Haller, H; Hüsig-Linde, C; Keller, F; Kielstein, JT; Kuse, E; Langhoff, A; Schöpke, T; Swoboda, S | 1 |
| Hovde, LB; Rotschafer, JC; Schafer, J; Simonson, D | 1 |
| Citron, DM; Goldstein, EJ; Nicolau, DP; Schooley, S; Stein, GE; Tyrrell, KL | 1 |
| Hovde, LB; Rotschafer, JC; Simonson, DA | 1 |
| Bezwada, P; Clark, LA; Schneider, S | 1 |
| Chang, ST; Chen, CC; Cheng, KC; Chuang, YC; Huang, HC; Shieh, CC; Yu, WL | 1 |
| Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T | 1 |
| Alexiadou, E; Grovaris, L; Lazaraki, G; Metallidis, S; Nikolaidis, J; Nikolaidis, P; Theodoridou, A; Topsis, D | 1 |
| Hatou, S; Yamada, M; Yoshida, J | 1 |
| Galles, AC; Jones, RN; Sader, HS | 1 |
| Evers, T; Holman, A; Lloyd, A | 1 |
| Carroll, DG; Carroll, DN | 1 |
| Arvis, P; Carlet, J; Choudhri, S; Garau, J; Kureishi, A; Le Berre, MA; Lode, H; Read, RC; Torres, A; Winter, J | 1 |
| Doshi, D; Grant, R; Janagap-Benson, C; Olson, W; Schein, J; Sikirica, V | 1 |
| Hatou, S; Minagawa, Y; Yamada, M; Yoshida, J; Yoshida, T | 1 |
| Dubois, V; Grellet, J; Nguyen, HA; Quentin, C; Saux, MC; Tulkens, PM; Van Bambeke, F; Van de Velde, S | 1 |
| Mullangi, R; Narasu, L; Shankar, BP; Srinivas, N | 1 |
| Kim, SY; Lee, YC; Park, YH | 1 |
| Asbell, PA; Epstein, SP; Sosa, AB | 1 |
| Scoper, SV | 1 |
| Qi, HM; Wei, MJ; Zhang, L; Zhao, CY | 1 |
| Aihara, M; Eguchi, S; Minami, K; Miyanaga, M; Miyata, K; Sawaguchi, S; Shiroma, H | 1 |
| Baietto, L; D'Avolio, A; De Rosa, FG; Di Perri, G; Garazzino, S; Patanella, S; Sciandra, M; Siccardi, M | 1 |
| Choi, JS; Joo, CK; Kim, KA; Lim, JA; Park, SH | 1 |
| Meletiadis, J; Papaioannidou, P; Roilides, E; Sein, T; Stergiopoulou, T; Tsiouris, I; Walsh, TJ | 1 |
| Ariza, J; Cabellos, C; Cabo, J; Euba, G; Gudiol, F; Murillo, O; Pachón, ME; Tubau, F; Verdaguer, R | 1 |
| García-Rodríguez, JA; Lázaro, FG; Muñoz-Bellido, JL; Rodríguez-Tarazona, RE | 1 |
| Hori, Y; Inoue, T; Kubota, A; Maeda, N; Nakazawa, T; Nishida, K; Sakamoto, M; Tano, Y; Yokokura, S | 1 |
| Chen, YC; Ho, CC; Hu, FC; Luh, KT; Yang, PC; Yu, CJ | 1 |
| Allen, GP; Hankins, CD | 1 |
| Carmona, IT; Diz Dios, P; Limeres Posse, J; Núñez Otero, V | 1 |
| Chen, WL; Hu, FR; Tsai, TH | 1 |
| Blondeau, JM; Borsos, SD; Hesje, CK | 1 |
| Carda-Broch, S; Esteve-Romero, J; Rambla-Alegre, M | 1 |
| Fisher, AC; Grant, R; Gu, A; Mody, SH; Ng, D; Raut, M; Schein, J; Sengupta, A; Sheng Duh, M; Signorovitch, JE | 1 |
| Anisimov, BI; Ryzhko, IV; Trishina, AV; Tsuraeva, RI | 1 |
| Berdeaux, G; Khoshnood, B; Kodjikian, L; Lafuma, A; Laurendeau, C | 1 |
| Chang, CM; Chen, PC; Chen, PL; Ko, WC; Lauderdale, TL; Lee, CC; Lee, HC; Lee, NY; Wu, CJ | 1 |
| Arezina, R; Camm, AJ; Harada, T; Lorch, U; Naseem, A; Taubel, J; Wang, D | 1 |
| Beksac, MS; Katlan, D; Kir, S; Nemutlu, E; Ozyuncu, O | 2 |
| Chan, RC; Chang, KC; Yew, WW | 1 |
| Huang, X; Li, Y; Shi, R; Yao, L; Zhang, G | 1 |
| Hsueh, PR; Lee, PI; Yang, JC | 1 |
| Arvis, P; Hampel, B; Judlin, P; Liao, Q; Liu, Z; Reimnitz, P | 1 |
| Andreu, I; Aranda, A; Ariza, A; Blanca-Lopez, N; Doña, I; Mayorga, C; Rosado, A; Torres, MJ | 1 |
| Schafer, KR; Wispelwey, B | 1 |
| Barbounakis, E; Kofteridis, DP; Lionakis, S; Maraki, S; Ntaoukakis, M; Ntasis, E; Samonis, G | 1 |
| Aracil, B; Campos, J; Cuevas, O; de Abajo, F; García-Cobos, S; Lázaro, E; Ortega, A; Oteo, J | 1 |
| Baba, S; Fujisawa, T; Harabuchi, Y; Ikeda, F; Kobayashi, T; Kurono, Y; Nishimura, T; Suzuki, K; Ubukata, K; Yamanaka, N | 1 |
| Bhagunde, P; Chang, KT; Ledesma, KR; Nikolaou, M; Singh, R; Tam, VH | 1 |
| Kim, SJ; Toma, HS | 1 |
| Ghasemzadeh, A; Mobarez, AM; Taghvaei, T; Talebi Bezmin Abadi, A | 1 |
| Decramer, M; Peetermans, WE; Simoens, S; van Bleyenbergh, P; Verhaegen, J | 1 |
| Gerding, DN; Johnson, S; Nagaro, K; Phillips, ST; Sambol, SP | 1 |
| Baik, GH; Jung, HC; Kim, GH; Kim, HB; Kim, JM; Kim, JY; Kim, NY; Kim, SJ; Lee, DH; Nam, RH; Song, IS | 1 |
| Biedenbach, DJ; Farrell, DJ; Jones, RN; Liverman, LC | 1 |
| Dan, M; Rosenberg, S; Samra, Z | 1 |
| Chamseddin, C; Jira, TH | 1 |
| Green, K; Low, DE; McGeer, A; Melano, R; Patel, SN; Pillai, DR; Tyrrell, GJ | 1 |
| Chung, HS; Han, SK; Kim, DK; Kim, JY; Kim, YW; Lee, CH; Lee, CT; Lee, J; Lee, JH; Lee, SM; Yang, SC; Yim, JJ; Yoo, CG; Yoon, HI | 1 |
| Cremades, R; Galiana, A; García-Pachón, E; López, P; Rodríguez, JC; Royo, G; Ruiz-García, M | 1 |
| Berning, M; Krasz, S; Labenz, J; Miehlke, S; Morgner, A | 1 |
| Alekperov, SI; Boĭko, ÉV; Fokina, DV; Reĭtuzov, VA | 1 |
| Furukawa, T; Goto, H; Ito, N; Miyake, T; Tajima, K | 1 |
| Biedenbach, DJ; Farrell, DJ; Flamm, RK; Jones, RN; Liverman, LC; McIntyre, G | 1 |
| Chen, X; Guo, X; Shi, G; Wang, H; Wang, S; Zhang, X | 1 |
| Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA | 1 |
| Hsueh, PR; Ko, WC; Liao, CH; Lu, JJ | 1 |
| Fukuda, M; Hori, Y; Inatomi, T; Kinoshita, S; Kubota, A; Maeda, N; Nakazawa, T; Nishida, K; Ohashi, Y; Satake, Y; Shimazaki, J; Shimomura, Y; Uno, T; Yamada, M | 1 |
| Chavda, K; Drlica, K; Hussain, S; Kerns, RJ; Kreiswirth, BN; Kurepina, N; Malik, M; Shah, N; Zhao, X | 1 |
| Malithong, A; Phiboonbanakit, D; Santiwatanakul, S; Srisangchan, P; Srisurat, N; Susaengrat, W; Tantisiriwat, W; Thamlikitkul, V; Thunyaharn, S; Tiengrim, S | 1 |
| Absi, M; Ghareeb, H; Khalil, A; Ruegg, UT | 1 |
| Ayaki, M; Iwasawa, A; Niwano, Y | 1 |
| Bourdon, O; Chauny, JV; De Lauzanne, A; Doit, C; Géréral, T; Lorrot, M; Prot-Labarthe, S | 1 |
| Castanheira, M; Farrell, DJ; Jones, RN; Turner, LL | 1 |
| Albini, A; Fasani, E; Maraschi, F; Migliavacca, R; Nucleo, E; Pretali, L; Profumo, A; Speltini, A; Sturini, M | 1 |
| Fortier, LC; Meessen-Pinard, M; Sekulovic, O | 1 |
| Bukatina, AA; Galkina, KY; Isaeva, YD; Makarova, MV; Moroz, AM; Nosova, EY | 1 |
| Gomez-Gutierrez, P; Lupala, CS; Perez, JJ | 1 |
| Kawasaki, S; Mito, T; Ohashi, Y; Suzuki, T; Tasaka, Y; Uda, T; Uno, T | 1 |
| Bowker, KE; Garvey, MI; Macgowan, AP; Noel, AR; Tomaselli, SG | 1 |
| Blanco, AR; Papa, V; Spoto, CG; Sudano Roccaro, A | 1 |
| Jiang, RH; Li, L; Xu, HB | 1 |
| Ahmad, Z; Grosset, JH; Minkowski, A; Nuermberger, EL; Peloquin, CA; Tyagi, S | 1 |
| Chung, JL; Kim, BY; Lee, JH; Lim, EH; Mah, FS; Seo, KY; Song, SW | 1 |
| Ohashi, Y; Suzuki, T | 1 |
| Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV | 1 |
| Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Papaioannou, M; Pitsiou, G; Sionidou, M | 1 |
| Chan Kim, K; Choi, JC; Choi, SB; Choi, WI; Heo, EY; Hwang, YI; Jang, SH; Jeon, K; Jung, KH; Kang, YA; Ki, YW; Kim, KU; Kim, SJ; Kim, YH; Koh, WJ; Kwon, YS; Lee, CH; Lee, J; Lee, JH; Lee, SH; Lee, YS; Ryu, YJ; Shim, TS; Um, S; Yim, JJ; Yoo, KH | 1 |
| Chang, CH; Chou, HW; Lai, MS; Lee, JJ; Shau, WY; Wang, JL | 1 |
| Budnitz, DS; Jones, SC; Mehta, H; Sorbello, A | 1 |
| Albini, A; Fasani, E; Maraschi, F; Pretali, L; Profumo, A; Speltini, A; Sturini, M | 1 |
| Jiang, B; Li, Y; Qiao, SS; Qu, Y; Wang, SH; Xie, YC; Xu, CL; Zhang, JY; Zhao, Y | 1 |
| Helmy, SA | 1 |
| Schluger, NW | 1 |
| Lu, J; Pang, Y; Wang, Y; Zhang, Z; Zhao, Y | 1 |
| Gratz, J; Heysell, SK; Houpt, ER; Kibiki, GS; Kumburu, H; Mpagama, SG; Ndusilo, N; Peloquin, CA; Stroup, S | 1 |
| Chung, WS; Han, KE; Kim, EK; Kim, S; Kim, T; Kim, TI | 1 |
| Alshammari, TM; Caffrey, AR; LaPlante, KL; Larrat, EP; Morrill, HJ; Quilliam, BJ | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Kawasaki, S; Mitani, A; Mito, T; Ohashi, Y; Suzuki, T; Tasaka, Y; Uda, T | 1 |
| Ang, TL; Song, M | 1 |
| Jeong, BH; Koh, WJ; Kwon, YS | 1 |
| Li, F; Liu, Y; Pu, C; Ren, X; Ren, Y; Sui, DJ; Sun, L; Sun, T; Wang, R; Yang, Z | 1 |
| Bulcun, E; Çimen, D; Ekici, A; Ekici, M; Güngör, Ö | 1 |
| Adrián Cataldi, A; Di Giulio, ÁB; Imperiale, BR; Morcillo, NS | 1 |
| Bielory, L; Kumar, S; Syed, BA | 1 |
| Djurdjevic, P; Ivanovic, N; Jakovljevic, I; Jelikic-Stankov, M; Joksovic, L | 1 |
| Haruki, T; Inoue, Y; Matsuura, K; Miyazaki, D; Noguchi, Y; Terasaka, Y; Yamagami, S | 1 |
| Chan, KA; Chang, CH; Chou, HW; Lai, CL; Lai, MS; Wang, JL | 1 |
| Carral, N; Lukas, JC; Oteo, I; Suarez, E | 1 |
| Beydemir, Ş; Söyüt, H; Türkeş, C | 1 |
| Akdogan, RA; Ayaz, T; Bedir, R; Rakici, H | 1 |
| Betlejewska-Kielak, K; Biernacka, J; Grudzień, M; Kłosińska-Szmurło, E; Mazurek, AP; Pluciński, F | 1 |
| Cetinkaya, B; Demirdag, K; Denk, A; Kalkan, A; Kilic, SS; Ozden, M | 1 |
| Donald, PR; Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Thee, S | 1 |
| Lee, CH; Lee, LN; Lee, MC; Wang, JT; Wang, JY; Yu, MC | 1 |
| Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS | 1 |
| Malik, S; Metchock, B; Posey, JE; Sikes, RD; Willby, M | 1 |
| Cai, X; Cui, J; Ni, W; Wei, C | 1 |
| Chang, SH; Chien, HI; Chien, ST; Hsu, CH; Hsueh, JC; Lee, PL; Lee, TM; Yang, MC; Yang, TF | 1 |
| Fukuda, M; Sasaki, H | 1 |
| Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, DH; Lee, JW; Lee, SM; Nam, RH; Park, JY | 1 |
| Beeton, ML; Chalker, VJ; Jones, LC; Maxwell, NC; Spiller, OB | 1 |
| Arnanz, C; de la Campa, AG; Ferrándiz, MJ; Martín-Galiano, AJ; Zimmerman, T | 1 |
| Huh, HJ; Jeon, K; Jeong, BH; Koh, WJ; Lee, H; Lee, NY; Park, HY | 1 |
| Cataldi, V; Cellini, L; Ciccaglione, AF; Di Bartolomeo, S; Di Campli, E; Di Giulio, M; Grossi, L; Marzio, L; Nostro, A | 1 |
| Chen, S; Chu, N; Fu, Y; Huang, H; Liang, Q; Ma, Y; Nie, W; Shang, Y | 1 |
| Bae, DW; Cho, SN; Dartois, V; Desta, KT; Eum, SY; Lee, SJ; Shin, SC | 1 |
| Chen, L; Chen, X; Jia, X; Li, N; Liu, W; Sun, H; Tong, H; Xiang, R; Xu, Y; Zhang, F; Zhang, J; Zhao, H | 1 |
| Choi, JC; Choi, SB; Choi, WI; Heo, E; Hwang, YI; Jang, SH; Jeon, K; Jung, KH; Kang, YA; Kim, KC; Kim, KU; Kim, SJ; Kim, YH; Koh, WJ; Kwon, YS; Lee, CH; Lee, HK; Lee, JH; Lee, SH; Ryu, YJ; Shim, TS; Um, S; Yim, JJ; Yoo, KH | 1 |
| Gent, JF; Holden, PN; Kong, Y; Murphy, TF; Pettigrew, MM; Sethi, S; Tsuji, BT | 1 |
| Grillon, A; Jehl, F; Kleinberg, M; Schramm, F | 1 |
| Chang, CM; Huang, CC; Ko, WC; Lee, CC; Lee, NY; Shih, HI; Tang, HJ; Wang, LR | 1 |
| Chong, SY; Chong, Y; Chung, HS; Hong, SG; Lee, K; Suh, Y | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Chen, S; Dong, L; Huang, H; Köser, CU; Moradigaravand, D; Parkhill, J; Peacock, SJ; Schön, T; Shang, Y; Wang, G; Wei, G; Yu, X | 1 |
| Chen, HH; Chiu, CH; Li, HC; Su, LH | 1 |
| Attisano, C; Cibinel, M; Furfaro, G; Giardini, F; Grandi, G; Grignolo, FM; Machetta, F; Panepinto, G; Pollino, C; Strani, G | 1 |
| Lim, SG; Tan, DW; Venkatraman, SS; Wong, TT | 1 |
| Hof, H | 1 |
| Head, BM; Meyers, AF; Rubinstein, E | 1 |
| Sterling, TR | 1 |
| Eguchi, H; Hotta, F; Ishimaru, M; Kogiso, M; Kusaka, S; Nishimura, K; Shimomura, Y; Yaguchi, T | 1 |
| Gisbert, JP; Marin, AC; McNicholl, AG; Nyssen, OP | 1 |
| Aubry, A; Bernard, C; Chauffour, A; Chavanet, P; El Helali, N; Jarlier, V; Maitre, T; Petitjean, G; Reibel, F; Veziris, N | 1 |
| Przybylski, DJ; Reeves, DJ | 1 |
| Bori, G; Jutte, PC; Kampinga, GA; Morata, L; Nannan Panday, PV; Soriano, A; Tornero, E; Wouthuyzen-Bakker, M | 1 |
| Mamatha, HG; Shanthi, V | 1 |
| Hardin, JW; Hyche, S; Magagnoli, J; Sutton, SS | 1 |
| Andres, S; Beckert, P; Heyckendorf, J; Hillemann, D; Kohl, TA; Köser, CU; Lange, C; Merker, M; Moradigaravand, D; Niemann, S; Olaru, ID; Parkhill, J; Peacock, SJ; Schleusener, V; Schön, T; Sturegård, E | 1 |
| Knoebel, RW; Lee, P; Pettit, NN; Pisano, J | 1 |
| Moussa, K; Schallhorn, JM; Shantha, J | 1 |
| Aktoğu Özkan, S; Biçmen, C; Çavuşoğlu, C; Eraç, B; Ermertcan, Ş; Hoşgör Limoncu, M; Yılmaz, FF | 1 |
| Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
| Cho, Y; Park, HS | 1 |
| Hammerschlag, MR; Huerta, N; Kohlhoff, SA | 1 |
| Alffenaar, JWC; Kosterink, JGW; Pranger, AD; van der Werf, TS | 1 |
| Chopra, V; Conlon, A; Flanders, SA; Gandhi, T; Malani, AN; Vaughn, VM | 1 |
| Alvarez-Cabrera, N; Blanc, L; Dartois, V; Dias-Freedman, I; Dietzold, J; Ho Liang, HP; Kaya, F; Kirschner, D; Linderman, J; Mina, M; O'Brien, P; Pienaar, E; Prideaux, B; Salgame, P; Sarathy, J; Savic, RM; Zimmerman, M | 1 |
| Huang, H; Huang, J; Jia, Y; Meng, L; Qiu, F; Sun, S | 1 |
| Kurz, X; McGettigan, P; Morales, D; Pacurariu, A; Pinheiro, L; Slattery, J | 1 |
| Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA | 1 |
| Capparelli, E; Catanzaro, DG; Rodwell, TC; Seifert, M | 1 |
| de la Campa, AG; Ferrándiz, MJ; García, MT; Valenzuela, MV | 1 |
| Macía, M; Navarro, D; Romay, AB; Trastoy, R; Treviño, M; Veiga, E | 1 |
| Attaran, B; Eskini, N; Esmaeili, M; Mohammadi, M; Sadeghi, M; Salehi, N; Sharifirad, A | 1 |
| Aung, KJM; Decroo, T; Kuaban, C; Noeske, J; Piubello, A; Rieder, HL; Van Deun, A | 1 |
| Cole, ST; Djumanov, D; Ferber, G; Fernandes, S; Prasad, K; Rosano, G; Sugiyama, A; Täubel, J; Van Langenhoven, L; Wibberley, H | 1 |
| Abushanab, L; Alshamayleh, N; Anzueto, A; Arabiat, H; Diab, A; Haddad, G; Jaber, W; Khalil, B; Kufoof, N; Momani, D; Mughrabi, M; Mulhem, A; Obaidat, M; Odat, E; Ramadan, M; Wadi Al Ramahi, J; Zahran, A | 1 |
| He, J; Hu, P; Li, N; Men, H; Wang, H; Wang, P; Xiang, J; Yu, X; Zhang, L; Zhang, S; Zheng, H; Zhou, F | 1 |
| Aubry, A; Bleibtreu, A; Fourniols, E; Funck-Brentano, C; Jaureguiberry, S; LLopis, B; Tissot, N; Zahr, N | 1 |
| Cheng, JW; Fan, X; Hou, X; Kudinha, T; Liang, GW; Liu, C; Shao, DH; Su, JR; Wang, Y; Wei, M; Xiao, M; Xiong, ZJ; Xu, YC; Yang, CX; Yang, QW; Yu, SY | 1 |
| Bennett, AC; Bennett, CL; Witherspoon, BJ | 1 |
| Frassineti, GL; Monti, M; Ruscelli, S; Silimbani, P | 1 |
| Dalamaga, M; Karampela, I | 1 |
| Dai, Q; Ding, J; Xie, S; Xu, Z; Zhang, Y; Zheng, R; Zhou, Y; Zuo, W | 1 |
| Shi, J; Si, X | 1 |
| de la Campa, AG; Domenech, M; García, MT; González-Camacho, F; Mateos-Martínez, P; Valenzuela, MV | 1 |
| Alffenaar, JW; Bruchfeld, J; Davies Forsman, L; Eliasson, E; Hoffner, S; Hong, C; Hu, Y; Ke, R; Kuhlin, J; Niward, K; Paues, J; Schön, T; Simonsson, USH; Werngren, J; Xu, B; Zheng, R; Zheng, X | 1 |
| de With, K; Georgi, U; Schmitt, J; Tesch, F | 1 |
| Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; van der Laan, LE; Winckler, JL | 1 |
| Qiujing, F; Weiwei, W | 1 |
| Beare, PA; Bloom, ME; Broeckel, RM; Flather, DP; Kendall, BL; Morris, CN; Offerdahl, DK; Scroggs, SLP | 1 |
| Cabañas, R; Domínguez-Ortega, J; Fiandor, A; González-Muñoz, M; Lluch-Bernal, M; Loli-Ausejo, D; Vílchez-Sánchez, F | 1 |
| Deans, KJ; Minneci, PC | 1 |
| Aarnio, M; Grönroos, J; Haijanen, J; Hurme, S; Ilves, I; Laukkarinen, J; Löyttyniemi, E; Marttila, H; Mattila, A; Meriläinen, S; Nordström, P; Paajanen, H; Pinta, T; Rantanen, T; Rautio, T; Rintala, J; Salminen, P; Sävelä, EL; Savolainen, H; Sippola, S; Sippola, T; Tammilehto, V | 1 |
| Chen, HC; Chen, KJ; Chen, YP; Chong, YJ; Kang, EY; Lai, CC; Liu, L; Sun, MH; Wu, WC | 1 |
| Chen, L; Du, X; Han, Y; Jian, Y; Xuan, J | 1 |
| Bucsa, C; Farcas, A; Huruba, M; Leucuta, DC; Mogosan, C; Sipos, M | 1 |
| Allen, GP; Deao, KM; Hill, SA; Schipelliti, SM; Tran, T | 1 |
| Dogan, A; Donmez, F | 1 |
| Blackman, A; Cáceres, T; Cachay, R; Gotuzzo, E; Maruri, F; Meza, E; Schwalb, A; Sterling, TR | 1 |
| Areia, M; Barrio, J; Beglinger, C; Bordin, D; Boyanova, L; Bujanda, L; Buzas, GM; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernandez, M; Doulberis, M; Fernandez-Salazar, L; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Jurecic, NB; Kunovský, L; Kupčinskas, J; Lamy, V; Lanas, A; Lasala, JP; Leja, M; Lerang, F; Lucendo, AJ; Marcos-Pinto, R; Marlicz, W; Megraud, F; Milivojevic, V; Molina-Infante, J; Morain, CO; Niv, Y; Nyssen, OP; Ortuño, J; Pérez Aísa, Á; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Sarsenbaeva, AS; Shvets, O; Simsek, I; Smith, S; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzhanina, L; Voynovan, I | 1 |
| Chen, X; Fu, L; Gao, T; Huo, F; Li, Q; Lu, Y; Pang, Y; Wang, B; Zhang, X | 1 |
| Chi, Z; Pan, X; Tang, W; Yin, Y; Zhao, M | 1 |
| Bhamare, P; Dunman, PM; Johnson, W; Kinn, B; Laskey, E; Mei, JA; Nolin, L; Stalker, C; Wozniak, RAF | 1 |
| Frings, A; Geerling, G; Goerke, P; Holtmann, C; MacKenzie, CR; Roth, M | 1 |
| Gao, J; Gao, M; Li, L; Liu, F; Liu, Y; Pang, Y; Shu, W; Sun, Y; Xie, L; Zhang, L | 1 |
| Afshar, B; Beeton, ML; Chalker, VJ; Day, J; Jensen, JS; Paukner, S; Rowlands, RS; Spiller, OB; Umer, TS; Windsor, H | 1 |
| Bykov, K; Fischer, MA; Gagne, JJ; Kattinakere-Sreedhara, S; Wang, J | 1 |
| He, Y; Li, X | 1 |
| Gunardi, WD; Moehario, LH; Nainggolan, IM; Nathania, I; Nusatia, ACM; Tjoa, E; Yasmon, A | 1 |
| Brankin, A; Colman, RE; Georghiou, SB; Seifert, M; Suresh, A; Uplekar, S; Walker, TM | 1 |
| Alghamdi, WA; Alsultan, A; Peloquin, C | 1 |
| Choi, SI; Jang, JY; Kim, N; Lee, DH; Lee, JW; Nam, RH; Song, CH | 1 |
| Chu, N; Gu, Y; Luo, H; Wang, Q; Xiao, Y; Yang, J; Zhang, J | 1 |
| Bulychev, VV; Bulycheva, EV; Pashkova, NA | 1 |
| Adams, KK; Clarke, LG; Shah, S | 1 |
| Chai, X; Sun, H; Wei, S; Xu, G | 1 |
| Algaidi, SH; Alghamdi, DI; Algheffari, SG; Alzahrani, RA; Hafiz, AM; Thabit, AK | 1 |
| Aalhoul, F; Cotton, F; Fage, D | 1 |
27 review(s) available for moxifloxacin and levofloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Quinolone antibiotics.
Topics: | 2019 |
[Third and fourth generation fluoroquinolones].
Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Belgium; Biological Availability; Drug Monitoring; Drug Resistance; Fluoroquinolones; Gemifloxacin; Humans; Intestinal Absorption; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Patient Selection; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors; Treatment Outcome | 2001 |
Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2004 |
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Pneumonia; Quinolines; Respiratory Tract Infections | 2004 |
Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Meta-Analysis as Topic; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Quinolines; Rhinitis; Sinusitis; Streptococcus pneumoniae | 2005 |
[Pathogenesis, diagnosis and therapy of Legionella infections].
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Aza Compounds; Azithromycin; Ciprofloxacin; Diagnosis, Differential; DNA, Bacterial; Fluoroquinolones; Humans; Incidence; Legionella; Legionella pneumophila; Legionellosis; Legionnaires' Disease; Levofloxacin; Moxifloxacin; Ofloxacin; Polymerase Chain Reaction; Quinolines; Serotyping; Virulence | 2006 |
Interactions between warfarin and three commonly prescribed fluoroquinolones.
Topics: Aza Compounds; Ciprofloxacin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluoroquinolones; Humans; International Normalized Ratio; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Warfarin | 2008 |
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Topics: Administration, Topical; Anti-Bacterial Agents; Aza Compounds; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2008 |
Efficacy of fluoroquinolones against pathogenic oral bacteria.
Topics: Aza Compounds; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Mouth Diseases; Moxifloxacin; Ofloxacin; Oral Medicine; Quinolines | 2009 |
[Efficacy of moxifloxacin in treating bacterial conjunctivitis: a meta-analysis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Odds Ratio; Ofloxacin; Ophthalmic Solutions; Patient Dropouts; Placebos; Quinolines; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Treatment Failure; Treatment Outcome | 2010 |
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
Topics: Antitubercular Agents; Aza Compounds; Bacterial Proteins; DNA Gyrase; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Sensitivity and Specificity; Tuberculosis, Multidrug-Resistant | 2010 |
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Proton Pump Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Retreatment | 2010 |
Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Topics: Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumonia, Bacterial; Primary Health Care; Quinolines; Streptococcus pneumoniae | 2010 |
[Current value of quinolones in Helicobacter pylori therapy].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2011 |
Second and third line treatment options for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Moxifloxacin; Ofloxacin; Rifabutin; Rifamycins; Rifaximin; Salvage Therapy; Virulence Factors | 2014 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Current options and emerging therapies for anterior ocular inflammatory disease.
Topics: Anti-Infective Agents; Antibodies, Monoclonal; Chemokine CCL11; Clinical Trials as Topic; Conjunctivitis, Allergic; Cyclosporine; Dibenzoxepins; Dry Eye Syndromes; Fluoroquinolones; Histamine H1 Antagonists; Humans; Immunotherapy; Levofloxacin; Moxifloxacin; Olopatadine Hydrochloride; Uveitis, Anterior | 2014 |
Fluoroquinolones for the treatment of tuberculosis in children.
Topics: Age Factors; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Listeria infections of the eye.
Topics: Animals; Anti-Bacterial Agents; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Listeria monocytogenes; Listeriosis; Moxifloxacin | 2017 |
Alternative pre-approved and novel therapies for the treatment of anthrax.
Topics: Alpha-Globulins; Anthrax; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Bacterial; Antitoxins; Bacillus anthracis; Bacterial Toxins; Daunorubicin; DNA Helicases; Doxorubicin; Drug Discovery; Fluoroquinolones; Humans; Interferon Inducers; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Polyketides; Serine Proteinase Inhibitors; Tilorone; Virulence | 2016 |
Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Proton Pump Inhibitors; Quinolones | 2017 |
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Treatment Outcome; Tuberculosis, Pulmonary | 2019 |
Brucellar reproductive system injury: A retrospective study of 22 cases and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Brucella; Brucellosis; China; Doxycycline; Drug Therapy, Combination; Female; Genitalia; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Rifampin | 2020 |
Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation.
Topics: Community-Acquired Infections; Cost-Benefit Analysis; Humans; Levofloxacin; Moxifloxacin; Pneumonia | 2021 |
The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Network Meta-Analysis; Tuberculosis; Tuberculosis, Pulmonary | 2022 |
28 trial(s) available for moxifloxacin and levofloxacin
| Article | Year |
|---|---|
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Brazil; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis, Pulmonary | 2008 |
Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cataract Extraction; Ciprofloxacin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Tissue Distribution | 2001 |
Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Azithromycin; Bronchoalveolar Lavage Fluid; Extravascular Lung Water; Female; Fluoroquinolones; Humans; Levofloxacin; Lung; Macrophages, Alveolar; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Urea | 2004 |
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines | 2005 |
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Safety | 2006 |
Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Topics: Analysis of Variance; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Long QT Syndrome; Male; Moxifloxacin; Ofloxacin; Quinolines; Statistics, Nonparametric; Torsades de Pointes | 2006 |
Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Argentina; Aza Compounds; Brazil; Bronchitis, Chronic; Colombia; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Mexico; Middle Aged; Moxifloxacin; Ofloxacin; Peru; Prospective Studies; Quinolines; Treatment Outcome | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Single-Blind Method; Tuberculosis, Pulmonary | 2006 |
Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Doxycycline; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Levofloxacin; Macrolides; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Treatment Failure | 2006 |
Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Penicillin Resistance; Quinolines; Serum Bactericidal Test; Streptococcus pneumoniae | 2007 |
A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Topics: Administration, Oral; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Cost of Illness; Cost-Benefit Analysis; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Length of Stay; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
A comparison of fluoroquinolone penetration into human conjunctival tissue.
Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Conjunctiva; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Young Adult | 2010 |
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Metronidazole; Middle Aged; Moxifloxacin; Ofloxacin; Pelvic Inflammatory Disease; Quinolines; Treatment Outcome; Young Adult | 2010 |
In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Aza Compounds; Basophil Degranulation Test; Ciprofloxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Immediate; Immunologic Tests; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Radioimmunoassay; Sensitivity and Specificity; Young Adult | 2011 |
Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Azithromycin; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Levofloxacin; Middle Aged; Moxifloxacin; Nasopharynx; Ofloxacin; Prospective Studies; Quinolines; Staphylococcal Infections | 2011 |
Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cornea; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratoplasty, Penetrating; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2012 |
Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Republic of Korea; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2013 |
Epithelial wound healing after cataract surgery comparing two different topical fluoroquinolones.
Topics: Aged; Aza Compounds; Cataract Extraction; Cornea; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Quinolines; Tomography, Optical Coherence; Wound Healing | 2014 |
Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Moxifloxacin; Pneumonia; Prospective Studies | 2014 |
Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Area Under Curve; Cycloserine; Drug Monitoring; Fluoroquinolones; Healthy Volunteers; Humans; Kanamycin; Levofloxacin; Male; Moxifloxacin; Prothionamide; Pyrazinamide; Streptomycin; Young Adult | 2015 |
Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes.
Topics: Adult; Anti-Bacterial Agents; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Republic of Korea; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Effects of the Fluoroquinolones Moxifloxacin and Levofloxacin on the QT Subintervals: Sex Differences in Ventricular Repolarization.
Topics: Action Potentials; Adult; Algorithms; Anti-Bacterial Agents; Calcium Channels; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Gonadal Steroid Hormones; Healthy Volunteers; Heart; Humans; Levofloxacin; Long QT Syndrome; Male; Moxifloxacin; Potassium Channels; Retrospective Studies; Sex Characteristics | 2020 |
Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adult; Anti-Bacterial Agents; Appendectomy; Appendicitis; Drug Therapy, Combination; Ertapenem; Female; Follow-Up Studies; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Moxifloxacin; Tomography, X-Ray Computed; Young Adult | 2021 |
Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Prevalence; Republic of Korea; Tertiary Care Centers | 2023 |
387 other study(ies) available for moxifloxacin and levofloxacin
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Escherichia coli; Models, Molecular; Pseudomonas aeruginosa; Quantitative Structure-Activity Relationship; Quinolones; Staphylococcus aureus; Thermodynamics | 2004 |
Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
Topics: Anti-Infective Agents; Cyclopropanes; DNA Topoisomerase IV; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids; Quinolones | 2007 |
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Indicators and Reagents; Kinetics; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Omeprazole; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
Topics: Amidohydrolases; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Peptides; Pneumococcal Infections; Species Specificity; Streptococcus pneumoniae; Time Factors | 2007 |
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Streptococcus pneumoniae; Transformation, Bacterial | 2007 |
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
Topics: Drug Resistance, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Microbial Sensitivity Tests; Quinolones | 2007 |
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Topics: Animals; Anti-Bacterial Agents; Cell Line, Tumor; Drug Resistance, Multiple, Bacterial; Female; Humans; Methicillin Resistance; Mice; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2007 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Haemophilus Infections; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Mutation | 2007 |
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Topics: Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
Topics: Animals; Anti-Bacterial Agents; Bacteriolysis; Ceftriaxone; Cell Wall; Cerebrospinal Fluid; Choline; Daptomycin; Disease Models, Animal; Humans; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillin Resistance; Rabbits; Streptococcus pneumoniae; Treatment Outcome; Tritium | 2007 |
Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
Topics: Anti-Infective Agents; Bacterial Proteins; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli Proteins; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Plasmids | 2007 |
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
Topics: Amino Acid Motifs; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Conjugation, Genetic; Conserved Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Genes, rRNA; Methylation; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Norfloxacin; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2007 |
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae | 2007 |
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States | 2007 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Disease Models, Animal; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests | 2007 |
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.
Topics: Anti-Bacterial Agents; Clone Cells; Drug Resistance, Multiple, Bacterial; Electrophoresis, Polyacrylamide Gel; Erythromycin; Genes, Bacterial; Microbial Sensitivity Tests; Phenotype; Pneumococcal Infections; Serotyping; Spain; Streptococcus pneumoniae; Tetracycline Resistance | 2007 |
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Culture Media; DNA Gyrase; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Gene Expression Regulation, Bacterial; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2007 |
In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Topics: Animals; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Japan; Levofloxacin; Liver; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolines; Spleen | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Imipenem; Ketolides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
Antimicrobial susceptibilities and clinical sources of Dialister species.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Species Specificity; Veillonellaceae | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross Infection; DNA Transposable Elements; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid | 2007 |
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2008 |
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Cloning, Molecular; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Multigene Family; Sequence Analysis, DNA; Substrate Specificity | 2008 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
Topics: Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Streptococcus agalactiae; Taiwan | 2008 |
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Cefepime; Cefotaxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Egypt; Hawaii; Humans; Leptospira; Leptospirosis; Levofloxacin; Microbial Sensitivity Tests; Nicaragua; Ofloxacin; Tetracycline; Thailand | 2008 |
Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Genotype; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; Taiwan | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; Blood; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Taiwan | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Chromosomes, Bacterial; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Gram-Negative Bacterial Infections; Humans; Molecular Sequence Data; Sequence Homology, Amino Acid; Stenotrophomonas maltophilia | 2008 |
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Topics: Aminopyridines; Anti-Bacterial Agents; Fluoroquinolones; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma fermentans; Mycoplasma genitalium; Mycoplasma hominis; Mycoplasma Infections; Mycoplasma pneumoniae; Ureaplasma; Ureaplasma Infections | 2008 |
Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clostridioides difficile; Colony Count, Microbial; Cytotoxins; DNA Gyrase; Feces; Fluoroquinolones; Gastrointestinal Tract; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Ribotyping | 2009 |
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
Topics: Amino Acid Substitution; Base Sequence; DNA Gyrase; DNA Mutational Analysis; DNA Primers; DNA Probes; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Humans; Nucleic Acid Denaturation; Point Mutation; Polymerase Chain Reaction; Streptococcus pneumoniae; Thermodynamics | 2008 |
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid | 2009 |
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Respiratory Tract Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA | 2009 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Topics: Aza Compounds; Clostridioides difficile; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2009 |
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
Topics: Bacterial Proteins; Drug Resistance, Bacterial; Electroporation; Genotype; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Quinolones; Salmonella enterica | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines | 2009 |
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
Topics: Anti-Infective Agents; Bacteria; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Mutation; Prospective Studies; Spain; Streptococcal Infections; Streptococcus pyogenes | 2010 |
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
Topics: Absorption; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport, Active; Cell Line; Cell Membrane Permeability; Cyclosporins; Diffusion; Drug Interactions; Drug Resistance, Bacterial; Epithelial Cells; Fluoroquinolones; Kinetics; Lipids; Lung | 2010 |
SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Mutation; Plasmids; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Stenotrophomonas maltophilia | 2010 |
In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Macrolides; Microbial Sensitivity Tests; Penicillin G; Streptococcus pneumoniae; Streptococcus pyogenes; Triazoles | 2010 |
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Polymerase Chain Reaction; Quinolines; Streptococcus pneumoniae | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Taiwan | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Communicable Diseases, Emerging; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States | 2010 |
Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Outer Membrane Proteins; Bacterial Typing Techniques; Carrier Proteins; Child; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Molecular Epidemiology; Norfloxacin; Point Mutation; Portugal; Streptococcal Infections; Streptococcus pyogenes | 2010 |
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
Topics: Aminopyridines; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium avium Complex; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections; Mycobacterium kansasii; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Quinolines; Rifampin; Species Specificity | 2010 |
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
Topics: Acinetobacter baumannii; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Dibekacin; Hospitals, Military; Humans; Microbial Sensitivity Tests; Warfare | 2010 |
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Thiazoles; Topoisomerase II Inhibitors; Tuberculosis | 2010 |
Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line; Cell Line, Tumor; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Topoisomerase II Inhibitors | 2010 |
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin | 2010 |
Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.
Topics: Anti-Infective Agents; Chloramphenicol; Escherichia coli; Fluoroquinolones; Levofloxacin; Ofloxacin; Oxazines; Structure-Activity Relationship | 2010 |
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Fatal Outcome; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
Topics: Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2011 |
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2011 |
Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Thienopyridines; Topoisomerase II Inhibitors | 2011 |
Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Cell Line; Cell Survival; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Fluoroquinolones; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Staphylococcus; Stereoisomerism; Structure-Activity Relationship | 2011 |
Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety.
Topics: Anti-Bacterial Agents; Bacteria; Chemistry Techniques, Synthetic; Fluoroquinolones; Gemifloxacin; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Naphthyridines; Oximes | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Fluoroquinolones; Microbial Sensitivity Tests; Molecular Structure; Oximes; Structure-Activity Relationship | 2014 |
Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Penicillin Resistance; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2015 |
Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Levofloxacin; Moxifloxacin; Naphthyridines; Oximes; Pyrrolidines; Stereoisomerism | 2015 |
Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Fluoroquinolones; Oximes | 2016 |
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Rifamycins; Staphylococcus aureus; Structure-Activity Relationship | 2016 |
Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
Topics: Anti-Bacterial Agents; Bacteria; Catalytic Domain; Chemistry Techniques, Synthetic; Drug Design; Drug Resistance, Multiple; Humans; Hydrophobic and Hydrophilic Interactions; Keto Acids; Molecular Docking Simulation; Serum Albumin, Human; Structure-Activity Relationship | 2018 |
Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
Topics: Animals; Anti-Bacterial Agents; DNA Topoisomerases, Type II; Drug Discovery; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Protein Conformation; Pyridines; Sepsis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; ERG1 Potassium Channel; Escherichia coli; Female; Humans; Macaca fascicularis; Male; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred CBA; Microbial Sensitivity Tests; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae | 2018 |
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells | 2019 |
Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria.
Topics: | 2019 |
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbon; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Neisseria gonorrhoeae; Structure-Activity Relationship | 2020 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperidines; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus pneumoniae; Structure-Activity Relationship | 2022 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Aerobic; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 1999 |
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Enterobacter cloacae; Fluoroquinolones; Gatifloxacin; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 1999 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
Activities of antimicrobial agents against intracellular pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Fluoroquinolones; Gentamicins; Humans; Ketolides; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Penicillin G; Quinolines; Rifampin; Streptococcus pneumoniae; Tumor Cells, Cultured | 2000 |
Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Escherichia coli; Fluoroquinolones; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2000 |
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Female; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Rabbits; Streptococcus pneumoniae | 2001 |
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography.
Topics: Anti-Infective Agents; Aza Compounds; Biological Assay; Chromatography, High Pressure Liquid; Ciprofloxacin; Dose-Response Relationship, Drug; Enterobacter cloacae; Escherichia coli; Fluoroquinolones; Klebsiella; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Photochemistry; Quinolines | 2001 |
Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae | 2001 |
A whole blood bactericidal assay for tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Blood; Blood Bactericidal Activity; Culture Media; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Quinolines; Rifampin | 2001 |
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain | 2001 |
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Child, Preschool; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Lactams; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2001 |
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae | 2001 |
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
Topics: Amino Acid Substitution; Anti-Infective Agents; Aza Compounds; Bacteroides fragilis; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines | 2001 |
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Legionella; Legionellosis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifampin | 2001 |
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Oxazolidinones; Polymerase Chain Reaction; Quinolines; Sensitivity and Specificity; Staphylococcus aureus; Teicoplanin; Vancomycin | 2001 |
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 2001 |
Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Norfloxacin; Ofloxacin; Quinolines | 2001 |
Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.
Topics: Anti-Infective Agents; Aza Compounds; DNA Topoisomerases, Type I; Fluoroquinolones; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Staphylococcus aureus | 2002 |
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Electrocardiography; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Torsades de Pointes | 2001 |
Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Drug Resistance; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Norfloxacin; Ofloxacin; Penicillins; Quinolines; Streptococcal Infections; Streptococcus | 2001 |
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2002 |
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Streptococcus pneumoniae | 2002 |
Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Selection, Genetic; Streptococcus pneumoniae | 2002 |
AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Endpoint Determination; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2002 |
Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Ketolides; Lactams; Levofloxacin; Linezolid; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Oxazolidinones; Penicillin G; Pristinamycin; Quinolines; Streptococcus pneumoniae; Virginiamycin | 2002 |
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis | 2002 |
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Haemophilus influenzae; Korea; Levofloxacin; Microbial Sensitivity Tests; Moraxella; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Culture Media; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Predictive Value of Tests; Quinolines; Streptococcus pneumoniae | 2003 |
Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Time Factors | 2002 |
Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Aza Compounds; Colony-Forming Units Assay; Escherichia coli; Fluoroquinolones; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Serum Bactericidal Test; Species Specificity; Staphylococcus aureus; Staphylococcus epidermidis | 2003 |
In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ofloxacin; Oxazolidinones; Quinolines; Spain | 2003 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors | 2003 |
In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Genes, Bacterial; Gonorrhea; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Nalidixic Acid; Naphthyridines; Neisseria gonorrhoeae; Ofloxacin; Quinolines | 2003 |
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Streptococcus pneumoniae | 2003 |
A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function.
Topics: Administration, Oral; Anti-Bacterial Agents; Aza Compounds; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Formularies, Hospital as Topic; Gatifloxacin; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Corneal Ulcer; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2003 |
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Pharmacogenetics; Pneumococcal Infections; Probability; Quinolines; Reference Values; Regression Analysis; Sensitivity and Specificity; Streptococcus pneumoniae | 2003 |
Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
Topics: Aza Compounds; Base Sequence; Ciprofloxacin; DNA Gyrase; DNA Primers; DNA Topoisomerase IV; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Ofloxacin; Polymerase Chain Reaction; Quinolines | 2004 |
Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Female; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Neutropenia; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Treatment Failure | 2004 |
Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Body Fluids; Cells, Cultured; Colony Count, Microbial; Culture Media; DNA Topoisomerase IV; DNA, Bacterial; Epithelium; Fluoroquinolones; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Phenotype; Quinolines; Streptococcus pneumoniae | 2004 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Wound Infection | 2004 |
Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Colony Count, Microbial; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Lung; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Spleen; Streptococcus pneumoniae | 2004 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cornea; Drug Resistance, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Staphylococcal Infections | 2004 |
Recurrent tendinitis after treatment with two different fluoroquinolones.
Topics: Achilles Tendon; Aged; Anti-Infective Agents; Asthma; Aza Compounds; Female; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Recurrence; Tendinopathy; Ultrasonography | 2004 |
Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Topics: Abdominal Abscess; Animals; Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Clindamycin; Disease Models, Animal; Fluoroquinolones; Injections, Subcutaneous; Levofloxacin; Male; Metronidazole; Mice; Moxifloxacin; Ofloxacin; Quinolines | 2004 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Movement; Chemokines; Chlamydia; Endothelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytes; Pneumonia, Bacterial; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha; Umbilical Veins | 2004 |
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Serratia Infections; Serratia marcescens | 2004 |
Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Enterobacteriaceae; Enterococcus faecalis; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2004 |
Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Body Temperature; Colony Count, Microbial; Disease Models, Animal; Female; Fluoroquinolones; Levofloxacin; Lung; Mice; Moxifloxacin; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Skin Temperature | 2004 |
Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; DNA, Bacterial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Streptococcus pneumoniae | 2004 |
Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching.
Topics: Anti-Infective Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Hydrogen-Ion Concentration; Levofloxacin; Moxifloxacin; Ofloxacin; Quality Control; Quinolines; Reference Standards; Reproducibility of Results | 2004 |
Penetration of newer quinolones in the empyema fluid.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Empyema, Pleural; Escherichia coli Infections; Fluoroquinolones; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pleural Effusion; Quinolines; Rabbits | 2004 |
Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2004 |
Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Structure-Activity Relationship; Time Factors | 2004 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Levofloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Sepsis; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Chromatography, High Pressure Liquid; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Half-Life; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line, Tumor; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Listeria monocytogenes; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Time Factors | 2005 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Ciprofloxacin; Fluoroquinolones; Heat-Shock Response; Humans; Kinetics; Levofloxacin; Macrophages; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2005 |
In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
Topics: Amoxicillin; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Sampling Studies; Sensitivity and Specificity; Streptococcus pneumoniae | 2005 |
Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Erythromycin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2005 |
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Moxifloxacin; Mutagenicity Tests; Naphthyridines; Ofloxacin; Quinolines; Selection, Genetic; Staphylococcus aureus; Streptococcus pneumoniae | 2005 |
[In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clindamycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Staphylococcus aureus; Staphylococcus epidermidis | 2005 |
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2005 |
Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Point Mutation; Quinolines; Sequence Analysis, DNA | 2005 |
Glucose homeostasis abnormalities associated with use of gatifloxacin.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones | 2005 |
Levofloxacin and moxifloxacin increase human gut colonization by Candida species.
Topics: Anti-Infective Agents; Aza Compounds; Candida; Drug Resistance, Microbial; Fluoroquinolones; Humans; Intestines; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits | 2006 |
Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Aza Compounds; Database Management Systems; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Sinusitis; Treatment Outcome; United States | 2006 |
Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations.
Topics: Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; Klebsiella pneumoniae; Levofloxacin; Lung; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae | 2005 |
Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Male; Mice; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae; Survival Analysis | 2006 |
Validation of a levofloxacin HPLC assay in plasma and dialysate for pharmacokinetic studies.
Topics: Anti-Bacterial Agents; Aza Compounds; Chromatography, High Pressure Liquid; Dialysis Solutions; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Renal Dialysis; Reproducibility of Results | 2006 |
In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
Topics: Anti-Bacterial Agents; Aza Compounds; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Fusidic Acid; Humans; In Vitro Techniques; Levofloxacin; Malaysia; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Rifampin; Staphylococcus aureus; Virginiamycin | 2005 |
Determination of the newer quinolones levofloxacin and moxifloxacin in plasma by high-performance liquid chromatography with fluorescence detection.
Topics: Anti-Bacterial Agents; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Vitreous Body | 2007 |
In vitro activity of fluoroquinolones against common respiratory pathogens.
Topics: Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Serum Bactericidal Test; Streptococcus pneumoniae | 2006 |
Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Topics: Adult; Area Under Curve; Aza Compounds; Bronchi; Computer Simulation; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Humans; Levofloxacin; Lung; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Moxifloxacin prophylaxis in neutropenic patients.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteremia; Clostridioides difficile; Enterocolitis, Pseudomembranous; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Moxifloxacin; Neutropenia; Ofloxacin; Quinolines | 2006 |
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Horses; Humans; Injections, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2006 |
Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?
Topics: Aged; Aged, 80 and over; Aza Compounds; Case-Control Studies; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines | 2006 |
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
In vitro development of resistance to DX-619 and other quinolones in enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Pyrrolidines; Quinolines; Quinolones; Sequence Analysis, DNA | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae | 2007 |
Photophysical and phototoxic properties of the antibacterial fluoroquinolones levofloxacin and moxifloxacin.
Topics: 3T3 Cells; Animals; Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Radiation; Erythrocytes; Fluoroquinolones; Humans; Levofloxacin; Lipid Peroxidation; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Photolysis; Photosensitizing Agents; Quinolines; Ultraviolet Rays | 2004 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutagenicity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Cross Infection; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Risk Factors | 2007 |
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin | 2007 |
Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Culture Media; Epithelium; Fluoroquinolones; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2007 |
Delayed intraocular foreign body removal without endophthalmitis during Operations Iraqi Freedom and Enduring Freedom.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Combined Modality Therapy; Endophthalmitis; Eye Enucleation; Eye Foreign Bodies; Eye Injuries, Penetrating; Female; Fluoroquinolones; Follow-Up Studies; Humans; Iraq; Levofloxacin; Male; Middle Aged; Military Medicine; Military Personnel; Moxifloxacin; Ofloxacin; Postoperative Complications; Prognosis; Quinolines; Retrospective Studies; Risk Factors; Time Factors; Visual Acuity; Vitrectomy; Vitreoretinopathy, Proliferative; Warfare | 2007 |
Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Aza Compounds; Cell Line; Extracellular Space; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Levofloxacin; Lysosomes; Monocytes; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus | 2007 |
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Electrophysiologic Techniques, Cardiac; Fluoroquinolones; Heart Conduction System; In Vitro Techniques; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Rabbits; Torsades de Pointes | 2007 |
Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Ciprofloxacin; Drug Combinations; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Preservatives, Pharmaceutical; Quinolines; Staphylococcus aureus | 2007 |
Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteriological Techniques; Cell Count; Cell Survival; Cells, Cultured; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; Epithelium, Corneal; Fluoroquinolones; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Quinolines; Serratia marcescens; Staphylococcus aureus | 2007 |
Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Anuria; Aza Compounds; Critical Care; Critical Illness; Female; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Male; Metabolic Clearance Rate; Middle Aged; Moxifloxacin; Multiple Organ Failure; Ofloxacin; Quinolines; Renal Dialysis; Sepsis | 2006 |
In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Quinolines; Streptococcus pneumoniae | 2008 |
Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens.
Topics: Abdominal Cavity; Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Serum Bactericidal Test | 2008 |
Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Colony Count, Microbial; DNA Topoisomerases; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Moxifloxacin; Mutation, Missense; Ofloxacin; Polymerase Chain Reaction; Quinolines; Sequence Analysis, DNA; Streptococcus pneumoniae | 2008 |
Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells.
Topics: Anti-Bacterial Agents; Aza Compounds; Biological Assay; Ciprofloxacin; Cornea; Corneal Stroma; Endothelial Cells; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cytokines; Disease Models, Animal; Fluoroquinolones; Levofloxacin; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Distress Syndrome | 2008 |
Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis.
Topics: Animals; Anti-Inflammatory Agents; Aza Compounds; Cells, Cultured; Conjunctivitis; Endotoxins; Fluoroquinolones; Gatifloxacin; Immunologic Factors; Keratitis; Levofloxacin; Lipopolysaccharides; Macrophages, Peritoneal; Male; Methicillin Resistance; Mice; Mice, Inbred C3H; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Tumor Necrosis Factor-alpha | 2008 |
Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty.
Topics: Anti-Bacterial Agents; Arthroplasty, Replacement, Hip; Aza Compounds; Bone and Bones; Chromatography, High Pressure Liquid; Female; Fluoroquinolones; Humans; Injections, Intravenous; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Osteomyelitis; Quinolines | 2007 |
In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacteria; Child; Conjunctiva; Drug Resistance, Microbial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2008 |
Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
Topics: Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Predictive Value of Tests; Quinolines; Stenotrophomonas maltophilia | 2008 |
A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Female; Fluoroquinolones; Health Care Costs; Hospitalization; Humans; Infusions, Intravenous; Insurance Claim Review; Length of Stay; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Research Design; Retrospective Studies; Treatment Outcome; United States | 2008 |
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Topics: Aza Compounds; Conjunctiva; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, MDR; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Staphylococcus epidermidis | 2008 |
Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes.
Topics: Anti-Bacterial Agents; Aza Compounds; Cell Line, Tumor; Colony Count, Microbial; Cytoplasm; Fluoroquinolones; Humans; Levofloxacin; Listeria monocytogenes; Microbial Viability; Monocytes; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2008 |
Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study.
Topics: Administration, Oral; Analytic Sample Preparation Methods; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Sensitivity and Specificity | 2008 |
Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Aza Compounds; Cefazolin; Cell Count; Cornea; Endothelium, Corneal; Fluoroquinolones; Injections; Levofloxacin; Microscopy, Electron, Scanning; Moxifloxacin; Ofloxacin; Quinolines; Rabbits | 2008 |
Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Cell Survival; Ciprofloxacin; Conjunctiva; Drug Evaluation, Preclinical; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tetrazolium Salts; Thiazoles | 2008 |
Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes.
Topics: Animals; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Ciprofloxacin; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Fluoroquinolones; Gatifloxacin; Humans; Isoenzymes; Levofloxacin; Microsomes, Liver; Molecular Structure; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results | 2008 |
Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV.
Topics: Acetamides; Anti-Bacterial Agents; Antibiotics, Antitubercular; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Oxazolidinones; Quality Control; Quinolines; Reference Standards; Reproducibility of Results; Rifampin; Solutions; Solvents; Spectrophotometry, Ultraviolet | 2009 |
The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacteria, Aerobic; Ciprofloxacin; Conjunctiva; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus.
Topics: Anti-Bacterial Agents; Antifungal Agents; Aspergillus fumigatus; Aza Compounds; Candida albicans; Ciprofloxacin; Drug Antagonism; Drug Synergism; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Foreign Bodies; Levofloxacin; Male; Microbial Sensitivity Tests; Microbial Viability; Models, Animal; Moxifloxacin; Ofloxacin; Quinolines; Rats; Rats, Wistar; Staphylococcal Infections; Time Factors | 2009 |
Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Topics: Anti-Bacterial Agents; Aza Compounds; Brucella melitensis; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Norfloxacin; Ofloxacin; Quinolines; Sequence Analysis, DNA | 2009 |
Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Conjunctiva; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Preoperative Care; Quinolines | 2009 |
Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Bacterial Agents; Antitubercular Agents; Aspartate Aminotransferases; Aza Compounds; Ethambutol; Female; Fluoroquinolones; Hepatic Insufficiency; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Streptomycin; Treatment Outcome; Tuberculosis; Young Adult | 2009 |
Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Neisseria gonorrhoeae; Ofloxacin; Quinolines; Selection, Genetic | 2009 |
Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Survival; Cells, Cultured; Ciprofloxacin; Electric Impedance; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2010 |
Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Topics: Anti-Bacterial Agents; Aza Compounds; Benzalkonium Compounds; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2009 |
Validation of a MLC method with fluorescence detection for the determination of quinolones in urine samples by direct injection.
Topics: Anti-Bacterial Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluorescence; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Reproducibility of Results | 2009 |
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Ambulatory Care; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Costs and Cost Analysis; Female; Fluoroquinolones; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Outpatients; Pneumonia; Quinolines; Young Adult | 2010 |
[Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Mice; Moxifloxacin; Ofloxacin; Plague; Quinolines; Species Specificity; Time Factors; Yersinia pestis | 2009 |
Colonisation of fluoroquinolone-resistant Haemophilus influenzae among nursing home residents in southern Taiwan.
Topics: Aged; Aza Compounds; beta-Lactamases; Colony Count, Microbial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Female; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Male; Moxifloxacin; Nursing Homes; Ofloxacin; Prospective Studies; Quinolines; Risk Factors; Serotyping; Taiwan | 2010 |
Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Cefepime; Cefoperazone; Cephalosporins; Female; Fetal Blood; Fluoroquinolones; Humans; Infant, Newborn; Injections, Intravenous; Levofloxacin; Maternal-Fetal Exchange; Moxifloxacin; Ofloxacin; Pregnancy; Pregnancy Complications, Infectious; Quinolines | 2010 |
Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime.
Topics: Adult; Amniocentesis; Amniotic Fluid; Anti-Bacterial Agents; Aza Compounds; Cefixime; Female; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Pregnancy; Quinolines; Statistics, Nonparametric | 2010 |
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gemifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Sequence Analysis, Protein; Taiwan; Tetracyclines; Tigecycline | 2010 |
Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Candida albicans; Dioxolanes; Feces; Fluoroquinolones; Gastrointestinal Tract; Levofloxacin; Male; Mice; Mice, Inbred ICR; Models, Animal; Moxifloxacin; Ofloxacin; Piperazines; Quinolines; Sodium Chloride | 2011 |
Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Aza Compounds; Bacteremia; Drug Resistance, Bacterial; Drug Utilization; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Hospitals; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Spain; Young Adult | 2011 |
[Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mutation; Ofloxacin; Otorhinolaryngologic Diseases; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2010 |
Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Models, Biological; Models, Theoretical; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Staphylococcus aureus; Time Factors | 2011 |
Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Iran; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Young Adult | 2012 |
Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2011 |
Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; Cricetinae; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Male; Mesocricetus; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Prohibitins; Quinolines | 2011 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Republic of Korea; Tetracycline | 2011 |
JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2011 |
Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Doxycycline; Erythromycin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results; Roxithromycin; Tetracycline; Time Factors; Ureaplasma Infections; Ureaplasma urealyticum | 2011 |
Comparison of the chromatographic behavior of levofloxacin, ciprofloxacin and moxifloxacin on various HPLC phases.
Topics: Anti-Bacterial Agents; Aza Compounds; Calixarenes; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Indicators and Reagents; Ions; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Solutions | 2011 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2011 |
Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Topics: Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Chi-Square Distribution; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Odds Ratio; Ofloxacin; Quinolines; Recurrence; Remission Induction; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2011 |
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain; Tuberculosis | 2011 |
[The effectiveness of intraocular delivery of 5-fluoroquinolones for prophylaxis of intraocular infection].
Topics: Anti-Bacterial Agents; Aza Compounds; Eye Infections, Bacterial; Eye Injuries; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intraocular; Levofloxacin; Male; Military Medicine; Moxifloxacin; Ofloxacin; Quinolines; Warfare | 2011 |
Comparison of moxifloxacin and levofloxacin in an epithelial disorder model using cultured rabbit corneal epithelial cell sheets.
Topics: Amnion; Animals; Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Corneal Diseases; Epithelium, Corneal; Female; Fluoroquinolones; Levofloxacin; Models, Biological; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines; Rabbits; Swine; Wound Healing | 2012 |
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Geography; Haemophilus influenzae; Humans; Inhibitory Concentration 50; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Streptococcus pneumoniae | 2012 |
Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Space; Fluoroquinolones; Intracellular Space; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Peritonitis; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2012 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Eye Infections, Fungal; Eye Infections, Parasitic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2012 |
Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Proteins; Clostridioides difficile; Fluoroquinolones; Gemifloxacin; Glycosides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifamycins; Rifaximin; Taiwan; Vancomycin | 2012 |
Induction of mycobacterial resistance to quinolone class antimicrobials.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2012 |
Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Tract Infections; Thailand; Urinary Tract Infections | 2012 |
The effect of levofloxacin and moxifloxacin on cardiovascular functions of rats with streptozotocin-induced diabetes.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Biological Factors; Blood Glucose; Bradycardia; Cardiovascular System; Diabetes Mellitus, Experimental; Electrocardiography; Endothelium, Vascular; Fluoroquinolones; Heart; Heart Rate; Hypoglycemia; Intermediate-Conductance Calcium-Activated Potassium Channels; Levofloxacin; Male; Mesenteric Arteries; Moxifloxacin; Ofloxacin; Quinolines; Rats; Rats, Wistar; Small-Conductance Calcium-Activated Potassium Channels; Streptozocin | 2013 |
In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cefmenoxime; Cell Line; Cell Survival; Conjunctiva; Cornea; Dibekacin; Dose-Response Relationship, Drug; Epithelial Cells; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Naphthyridines; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines; Rabbits | 2012 |
Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases.
Topics: Adolescent; Antitubercular Agents; Aza Compounds; Child; Child, Preschool; Female; Fluoroquinolones; France; Hospitals, University; Humans; Infant; Levofloxacin; Male; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2012 |
Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcal Skin Infections; Staphylococcus aureus | 2012 |
Photodegradation of fluoroquinolones in surface water and antimicrobial activity of the photoproducts.
Topics: Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Photolysis; Quinolines; Tandem Mass Spectrometry | 2012 |
Evidence of in vivo prophage induction during Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; DNA, Viral; Feces; Fluoroquinolones; Genetic Variation; Genome, Viral; Humans; Levofloxacin; Lysogeny; Microbial Sensitivity Tests; Mitomycin; Molecular Sequence Data; Moxifloxacin; Myoviridae; Ofloxacin; Prophages; Quinolines; Sequence Analysis, DNA; Virus Activation | 2012 |
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Topics: Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gene Expression Regulation, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Russia; Tuberculosis, Pulmonary | 2013 |
Molecular determinants of the bacterial resistance to fluoroquinolones: a computational study.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Molecular Docking Simulation; Moxifloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Streptococcus pneumoniae | 2013 |
Moxifloxacin as postoperative prophylaxis for Enterococcus faecalis-induced endophthalmitis after cataract surgery in aphakic rabbits.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aphakia, Postcataract; Aza Compounds; Disease Models, Animal; Electroretinography; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Fluoroquinolones; Gram-Positive Bacterial Infections; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Phacoemulsification; Quinolines; Rabbits; Time Factors | 2013 |
Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Load; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Models, Theoretical; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Selection, Genetic; Streptococcus pneumoniae | 2013 |
Susceptibility of methicillin-resistant Staphylococci clinical isolates to netilmicin and other antibiotics commonly used in ophthalmic therapy.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Chloramphenicol; Drug Resistance; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Netilmicin; Quinolines; Staphylococcus epidermidis; Tobramycin; Vancomycin | 2013 |
Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Aza Compounds; China; Drug-Related Side Effects and Adverse Reactions; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Recurrence; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2013 |
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Levofloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis | 2013 |
Comparative intraocular penetration of 4 fluoroquinolones after topical instillation.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Area Under Curve; Aza Compounds; Azepines; Biological Availability; Chromatography, High Pressure Liquid; Conjunctiva; Cornea; Fluoroquinolones; Gatifloxacin; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Tissue Distribution; Vitreous Body | 2013 |
Combination effect of antibiotics against bacteria isolated from keratitis using fractional inhibitory concentration index.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefmenoxime; Corneal Ulcer; Drug Combinations; Drug Synergism; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas; Quinolines; Staphylococcus; Streptococcus; Tobramycin | 2013 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis | 2013 |
Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.
Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Respiratory Tract Infections | 2013 |
Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cohort Studies; Diabetes Complications; Female; Fluoroquinolones; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Middle Aged; Moxifloxacin; Odds Ratio; Propensity Score; Quinolines; Taiwan | 2013 |
US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug-Related Side Effects and Adverse Reactions; Emergency Service, Hospital; Female; Fluoroquinolones; Humans; Hypersensitivity; Levofloxacin; Male; Middle Aged; Moxifloxacin; Quinolines; United States | 2013 |
Environmental photochemistry of fluoroquinolones in soil and in aqueous soil suspensions under solar light.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Levofloxacin; Moxifloxacin; Photolysis; Soil; Soil Pollutants; Sunlight; Suspensions; Water | 2014 |
[Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Myasthenia Gravis; Quinolines; Retrospective Studies; Young Adult | 2013 |
Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers.
Topics: Acetamides; Adult; Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Drug Monitoring; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Limit of Detection; Linezolid; Male; Moxifloxacin; Norfloxacin; Oxazolidinones; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Tinidazole; Young Adult | 2013 |
Fluoroquinolones in the treatment of tuberculosis: which is best?
Topics: Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Quinolines; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence | 2014 |
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Sputum; Tanzania; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.
Topics: Adult; Aged; Alcoholism; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Comorbidity; Data Interpretation, Statistical; Databases, Factual; Female; Fluoroquinolones; Hospitals, Veterans; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Patient Safety; Quinolines; Retrospective Studies; Risk Factors; Socioeconomic Factors; United States; United States Department of Veterans Affairs | 2014 |
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Aza Compounds; Biotransformation; Chromatography, High Pressure Liquid; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Fluoroquinolones; Indoles; Injections, Intravenous; Levofloxacin; Male; Models, Animal; Moxifloxacin; Polypharmacy; Protein Kinase Inhibitors; Pyrroles; Quinolines; Rabbits; Spectrophotometry, Ultraviolet; Sunitinib | 2013 |
Ocular penetration and efficacy of levofloxacin using different drug-delivery techniques for the prevention of endophthalmitis in rabbit eyes with posterior capsule rupture.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Drug Delivery Systems; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Posterior Capsular Rupture, Ocular; Rabbits; Vitreous Body | 2014 |
Case of round pneumonia: pulmonary infarct and a rare situation that is similar with the lung cancer.
Topics: Diagnosis, Differential; Fluoroquinolones; Humans; Levofloxacin; Lung Neoplasms; Male; Middle Aged; Moxifloxacin; Pneumonia; Pulmonary Infarction; Radiography, Thoracic; Treatment Outcome; Young Adult | 2015 |
Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs.
Topics: Antitubercular Agents; Base Sequence; Colorimetry; Drug Resistance, Bacterial; Ethionamide; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Open Reading Frames; Rifabutin; Rifampin; Sequence Analysis, DNA; Tuberculosis | 2014 |
The effect of some fluoroquinolone family members on biospeciation of copper(II), nickel(II) and zinc(II) ions in human plasma.
Topics: Ciprofloxacin; Coordination Complexes; Copper; Fluoroquinolones; Humans; Ions; Levofloxacin; Moxifloxacin; Nickel; Ofloxacin; Zinc | 2014 |
Comparison of toxicities of moxifloxacin, cefuroxime, and levofloxacin to corneal endothelial cells in vitro.
Topics: Anti-Bacterial Agents; Cefuroxime; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Corneal; Enzyme-Linked Immunosorbent Assay; Fluoroquinolones; Humans; Inhibitory Concentration 50; Interleukin-6; Levofloxacin; Moxifloxacin | 2014 |
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; beta-Lactamase Inhibitors; Cardiovascular Diseases; Ciprofloxacin; Clarithromycin; Comorbidity; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Moxifloxacin; Risk; Taiwan | 2015 |
Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study.
Topics: Adult; Anti-Bacterial Agents; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Male; Medication Adherence; Middle Aged; Models, Statistical; Moraxella catarrhalis; Moxifloxacin; Respiratory Tract Infections; Streptococcus pneumoniae; Treatment Failure; Young Adult | 2015 |
Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium.
Topics: Aryldialkylphosphatase; Cefepime; Cefotaxime; Ceftizoxime; Cephalosporins; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Moxifloxacin | 2015 |
Physicochemical properties of lomefloxacin, levofloxacin, and moxifloxacin relevant to the biopharmaceutics classification system.
Topics: Anti-Bacterial Agents; Biopharmaceutics; Chemistry, Pharmaceutical; Electrochemistry; Fluoroquinolones; Gastrointestinal Tract; Humans; Hydrogen-Ion Concentration; Levofloxacin; Models, Molecular; Molecular Conformation; Moxifloxacin; Permeability; Phosphates; Potentiometry; Protons; Quantum Theory; Solubility; Solvents; Static Electricity; Temperature | 2014 |
In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey.
Topics: Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Doxycycline; Fluoroquinolones; Humans; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Quinolones; Serotyping; Turkey | 2015 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Linear Models; Longitudinal Studies; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Taiwan; Tuberculosis, Pulmonary; Young Adult | 2015 |
Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis | 2015 |
A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cross Infection; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Minocycline; Monte Carlo Method; Moxifloxacin; Pneumonia; Sputum; Stenotrophomonas maltophilia; Tigecycline | 2015 |
Molecular Characterization of Community- and Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Isolates in Southern Taiwan.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Base Sequence; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gene Expression Regulation, Bacterial; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Moxifloxacin; Staphylococcal Infections; Taiwan | 2015 |
Effects of Fluoroquinolone-Based Antibacterial Ophthalmic Solutions on Corneal Wound Healing.
Topics: Animals; Anti-Bacterial Agents; Cell Proliferation; Cell Survival; Corneal Injuries; Disease Models, Animal; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Rabbits; Time Factors; Wound Healing | 2015 |
High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Asparagine; Aspartic Acid; DNA Gyrase; Female; Fluoroquinolones; Gene Expression; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Point Mutation; Treatment Outcome | 2015 |
Antibiotic Resistance among Clinical Ureaplasma Isolates Recovered from Neonates in England and Wales between 2007 and 2013.
Topics: Anti-Bacterial Agents; Chloramphenicol; Ciprofloxacin; Drug Resistance, Bacterial; England; Epidemiological Monitoring; Fluoroquinolones; Gentamicins; Humans; Infant; Infant, Newborn; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Retrospective Studies; Tetracycline; Ureaplasma; Ureaplasma Infections; Wales | 2016 |
Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae.
Topics: Acetyl-CoA Carboxylase; Acetyltransferases; Anti-Bacterial Agents; Bacterial Proteins; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Fructosephosphates; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Gene Ontology; Glycolysis; Hydrogen Peroxide; Iron; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Annotation; Moxifloxacin; Oxidative Stress; Pyruvate Oxidase; Pyruvic Acid; Streptococcus pneumoniae; Transcription, Genetic | 2016 |
Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2016 |
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Child; Ciprofloxacin; Clarithromycin; Drug Resistance, Multiple, Bacterial; Dyspepsia; Female; Fluoroquinolones; Gastric Fundus; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pyloric Antrum; Rifabutin; Tetracycline; Young Adult | 2016 |
[Detection of mutations in the gyrA and gyrB genes associated with fluoroquinolone-resistance among clinical isolates of Mycobacterium abscessus in China].
Topics: Aza Compounds; Base Sequence; China; DNA Gyrase; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Nontuberculous Mycobacteria | 2015 |
Development and validation of LC-ESI-MS/MS method for analysis of moxifloxacin and levofloxacin in serum of multidrug-resistant tuberculosis patients: Potential application as therapeutic drug monitoring tool in medical diagnosis.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Fluoroquinolones; Humans; Levofloxacin; Limit of Detection; Moxifloxacin; Tandem Mass Spectrometry; Tuberculosis, Multidrug-Resistant | 2016 |
[Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Topics: Anti-Bacterial Agents; Aza Compounds; Cefepime; Cephalosporins; China; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillins; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2016 |
Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Pulmonary Disease, Chronic Obstructive | 2016 |
Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Inhibitory Concentration 50; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas aeruginosa; Stenotrophomonas maltophilia | 2016 |
Increasing resistance to fluoroquinolones among Haemophilus species in Southern Taiwan.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Haemophilus influenzae; Haemophilus parainfluenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Taiwan | 2017 |
Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ceftazidime; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Membrane Transport Proteins; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Stenotrophomonas maltophilia; Ticarcillin; Tigecycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2017 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
Topics: Antitubercular Agents; China; DNA Gyrase; Drug Dosage Calculations; Drug Resistance, Bacterial; Fluoroquinolones; Gene Expression; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Pulmonary | 2016 |
Fluoroquinolone-nonsusceptible Streptococcus pneumoniae isolates from a medical center in the pneumococcal conjugate vaccine era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Disk Diffusion Antimicrobial Tests; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Heptavalent Pneumococcal Conjugate Vaccine; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Multilocus Sequence Typing; Pneumonia, Pneumococcal; Prospective Studies; Serogroup; Streptococcus pneumoniae; Topoisomerase II Inhibitors; Vaccines, Conjugate; Young Adult | 2017 |
Severe Ocular Bacterial Infections: A Retrospective Study Over 13 Years.
Topics: Anti-Bacterial Agents; Conjunctiva; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus | 2017 |
Sustained Antibiotic-Eluting Intra-Ocular Lenses: A New Approach.
Topics: Anti-Bacterial Agents; Drug Carriers; Drug Liberation; Eye, Artificial; Fluoroquinolones; Furans; Hydrophobic and Hydrophilic Interactions; Lenses, Intraocular; Levofloxacin; Methylene Chloride; Microscopy, Electron, Scanning; Moxifloxacin; Polyesters; Surface Properties | 2016 |
Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
A super-infection in the cornea caused by Stemphylium, Acremonium, and α-Streptococcus.
Topics: Acremonium; Aged; Anti-Infective Agents; Cefmenoxime; Coinfection; Cornea; Eye Infections, Fungal; Female; Fluoroquinolones; Humans; Keratitis; Levofloxacin; Moxifloxacin; Saccharomycetales; Streptococcus | 2017 |
Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Levofloxacin; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Treatment Outcome | 2017 |
Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Levofloxacin; Male; Middle Aged; Moxifloxacin; Neutropenia; Randomized Controlled Trials as Topic; Retrospective Studies | 2017 |
Moxifloxacin plus rifampin as an alternative for levofloxacin plus rifampin in the treatment of a prosthetic joint infection with Staphylococcus aureus.
Topics: Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Prosthesis-Related Infections; Retrospective Studies; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2018 |
Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; India; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence; Prospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2018 |
Appraisal of the cardiovascular risks of azithromycin: an observational analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Cardiovascular Diseases; Clarithromycin; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Risk Factors; Young Adult | 2017 |
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Bacterial Typing Techniques; Cohort Studies; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Genome, Bacterial; Genotype; Humans; Kanamycin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Phenotype; Rifampin; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing | 2018 |
Moxifloxacin versus levofloxacin for antibacterial prophylaxis in acute leukemia patients.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Female; Humans; Leukemia, Myeloid, Acute; Levofloxacin; Male; Middle Aged; Moxifloxacin; Neutropenia; Retrospective Studies | 2019 |
Blurry Vision and Eye Pain After Pterygium Surgery.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Eye Infections, Bacterial; Eye Pain; Female; Glucocorticoids; Humans; Indomethacin; Intraocular Pressure; Levofloxacin; Moxifloxacin; Ophthalmologic Surgical Procedures; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Pterygium; Scleritis; Vision Disorders; Visual Acuity | 2018 |
In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant; Turkey | 2018 |
Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Arrhythmias, Cardiac; Cefixime; Ciprofloxacin; Cohort Studies; Female; Fluoroquinolones; Heart Arrest; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Protective Factors; Republic of Korea; Risk Factors; Tachycardia, Ventricular; Ventricular Fibrillation; Ventricular Flutter | 2018 |
Topics: Anti-Bacterial Agents; Azithromycin; Cell Line; Chlamydial Pneumonia; Chlamydophila pneumoniae; Doxycycline; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Tetracyclines | 2019 |
The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study.
Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Ciprofloxacin; Clostridium Infections; Cohort Studies; Drug Prescriptions; Drug Resistance, Bacterial; Female; Fluoroquinolones; Hospitals; Humans; Levofloxacin; Male; Michigan; Moxifloxacin; Pneumonia; Retrospective Studies; Risk; Surveys and Questionnaires | 2019 |
Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
Topics: Animals; Antitubercular Agents; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Rabbits; Tandem Mass Spectrometry; Tuberculosis, Multidrug-Resistant | 2019 |
Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aortic Aneurysm, Thoracic; Aortic Dissection; Bayes Theorem; Child; Child, Preschool; Ciprofloxacin; Data Mining; Female; Fluoroquinolones; Humans; Infant; Infant, Newborn; Levofloxacin; Male; Middle Aged; Moxifloxacin; Pharmacovigilance; United States; United States Food and Drug Administration; Young Adult | 2019 |
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Case-Control Studies; Ciprofloxacin; Female; Fluoroquinolones; Humans; Incidence; Levofloxacin; Male; Middle Aged; Moxifloxacin; Norfloxacin; Ofloxacin; Peripheral Nervous System Diseases; Risk Factors; Sex Factors; United Kingdom | 2019 |
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Moxifloxacin; Ofloxacin; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Polymorphism, Single Nucleotide | 2019 |
Reactive Oxygen Species Production Is a Major Factor Directing the Postantibiotic Effect of Fluoroquinolones in Streptococcus pneumoniae.
Topics: DNA Cleavage; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Reactive Oxygen Species; Streptococcus pneumoniae | 2019 |
Prevalence of genital Mycoplasma and response to eradication treatment in patients undergoing assisted reproductive techniques.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Clindamycin; Doxycycline; Embryo Implantation; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Mycoplasma hominis; Mycoplasma Infections; Prevalence; Real-Time Polymerase Chain Reaction; Reproductive Techniques, Assisted; Semen Analysis; Sex Factors; Treatment Outcome; Ureaplasma Infections; Ureaplasma urealyticum; Young Adult | 2019 |
New insights into resistance of Helicobacter pylori against third- and fourth-generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations.
Topics: Anti-Bacterial Agents; DNA Gyrase; Drug Resistance, Bacterial; Gemifloxacin; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Molecular Docking Simulation; Moxifloxacin; Mutant Proteins; Mutation; Polymerase Chain Reaction; Protein Binding; Sequence Analysis, DNA | 2019 |
Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bangladesh; Cameroon; Child; Drug Administration Schedule; Female; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Niger; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Pneumonia; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2018 |
Phenotypic and molecular characterisation of a novel species,
Topics: Aged, 80 and over; Antitubercular Agents; Bacterial Proteins; Base Composition; Chaperonin 60; China; Cluster Analysis; Cytosol; DNA-Directed RNA Polymerases; DNA, Bacterial; DNA, Ribosomal; DNA, Ribosomal Spacer; Fatty Acids; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium Infections, Nontuberculous; Phylogeny; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Sputum | 2020 |
Development and validation of a UPLC-MS/MS method for simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma: Application to the therapeutic drug monitoring in osteoarticular infections.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Monitoring; Female; Humans; Levofloxacin; Limit of Detection; Male; Middle Aged; Moxifloxacin; Plasma; Reproducibility of Results; Rifampin; Tandem Mass Spectrometry | 2020 |
The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; China; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; DNA Gyrase; Drug Resistance, Bacterial; Enterotoxins; Fluoroquinolones; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Typing; Moxifloxacin; Vancomycin | 2020 |
Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and dru
Topics: Animals; Aortic Aneurysm; Ciprofloxacin; Dissection; Humans; Idiopathic Pulmonary Fibrosis; Levofloxacin; Moxifloxacin; United States; United States Food and Drug Administration | 2020 |
Letter to the Editor: Consideration on "An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin- association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administra
Topics: Aortic Aneurysm; Ciprofloxacin; Dissection; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; United States; United States Food and Drug Administration | 2020 |
Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
Topics: Antiviral Agents; COVID-19 Drug Treatment; Humans; Levofloxacin; Moxifloxacin; SARS-CoV-2 | 2020 |
Pulmonary and Skeletal Infection of
Topics: Adult; Bone and Bones; Cough; Female; Fever; Follow-Up Studies; Humans; Levofloxacin; Lung; Magnetic Resonance Imaging; Moxifloxacin; Multimodal Imaging; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Positron-Emission Tomography; Rare Diseases; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Benzodioxoles; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Levofloxacin; Moxifloxacin; Phenanthrenes; Streptococcus pneumoniae; Topoisomerase I Inhibitors | 2020 |
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pharmaceutical Preparations; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2021 |
Impact of safety warnings for fluoroquinolones on prescribing behaviour. Results of a cohort study with outpatient routine data.
Topics: Anti-Bacterial Agents; Cohort Studies; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Outpatients | 2021 |
Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB.
Topics: Adolescent; Anti-Bacterial Agents; Aza Compounds; Child; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Tuberculosis | 2020 |
Efficacy of moxifloxacin combined with levofloxacin in the treatment of drug-resistant tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Case-Control Studies; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Random Allocation; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2020 |
Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Animals; Anti-Bacterial Agents; Antiviral Agents; Cell Line; Chlorocebus aethiops; Ciprofloxacin; Coronavirus Infections; COVID-19 Drug Treatment; Enoxacin; Fluoroquinolones; Humans; Levofloxacin; Middle East Respiratory Syndrome Coronavirus; Moxifloxacin; SARS-CoV-2; Vero Cells | 2020 |
Basophil activation test in the diagnosis of hypersensitivity reactions to quinolones in a real-life setting.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Basophil Degranulation Test; Ciprofloxacin; Drug Hypersensitivity; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Norfloxacin; Quinolones; Skin Tests; Young Adult | 2021 |
Evolving Issues in the Use of Antibiotics for the Treatment of Uncomplicated Appendicitis.
Topics: Acute Disease; Anti-Bacterial Agents; Appendectomy; Appendicitis; Ertapenem; Humans; Levofloxacin; Moxifloxacin | 2021 |
Streptococcus pneumoniae endophthalmitis: clinical settings, antibiotic susceptibility, and visual outcomes.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cataract; Cataract Extraction; Ceftriaxone; Cefuroxime; Corneal Ulcer; Endophthalmitis; Eye Enucleation; Eye Injuries; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillins; Pneumococcal Infections; Retrospective Studies; Severity of Illness Index; Streptococcus pneumoniae; Taiwan; Tertiary Care Centers; Trabeculectomy; Treatment Outcome; Vancomycin; Vitrectomy | 2021 |
A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Adverse Drug Reaction Reporting Systems; Arthralgia; Ciprofloxacin; Connective Tissue Diseases; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Musculoskeletal Diseases; Myalgia; Norfloxacin; Ofloxacin; Pain; Risk Factors; Tendinopathy; Tendons; Young Adult | 2021 |
In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Doxycycline; Drug Resistance, Multiple, Bacterial; Ertapenem; Gentamicins; Gonorrhea; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Neisseria gonorrhoeae | 2021 |
Investigation of the effects of three different generations of fluoroquinolone derivatives on antioxidant and immunotoxic enzyme levels in different rat tissues.
Topics: Adenosine Deaminase; Animals; Antioxidants; Aspartate Aminotransferases; Catalase; Ciprofloxacin; COVID-19; Creatinine; Fluoroquinolones; Glucose; Glutathione; Glutathione Peroxidase; Levofloxacin; Lipid Peroxidation; Malondialdehyde; Moxifloxacin; Nalidixic Acid; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; SARS-CoV-2; Superoxide Dismutase; Triglycerides | 2022 |
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Peru; Pharmaceutical Preparations; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2021 |
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Penicillins; Prospective Studies; Proton Pump Inhibitors; Quinolones; Registries; Tetracycline | 2022 |
Molecular Characteristic of Both Levofloxacin and Moxifloxacin Resistance in
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA Gyrase; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Tuberculosis, Multidrug-Resistant | 2022 |
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Pneumonia; Quinolones; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary | 2022 |
Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates.
Topics: Anti-Bacterial Agents; Bacitracin; Drug Combinations; Erythromycin; Framycetin; Humans; Keratitis; Levofloxacin; Moxifloxacin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Tobramycin; Trimethoprim | 2022 |
Spectrum and resistance in bacterial infections of the ocular surface in a German tertiary referral center 2009-2019.
Topics: Anti-Bacterial Agents; Bacteria; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Gentamicins; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Retrospective Studies; Tertiary Care Centers | 2022 |
Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
Topics: Antitubercular Agents; Clofazimine; Creatinine; Diarylquinolines; Humans; Levofloxacin; Long QT Syndrome; Moxifloxacin; Nomograms; Tuberculosis, Multidrug-Resistant | 2022 |
Phenotypic and genotypic antimicrobial susceptibility patterns of the emerging human respiratory pathogen Mycoplasma amphoriforme isolated from the UK and Denmark.
Topics: Anti-Bacterial Agents; Denmark; Drug Resistance, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; United Kingdom | 2022 |
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospital; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitals; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Retrospective Studies; Suicidal Ideation; Suicide; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta.
Topics: Amino Acids; Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Quinolones; Salmonella; Salmonella enterica; Salmonella typhi; Typhoid Fever | 2022 |
In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Genotype; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization | 2022 |
Determining in vitro and ex vivo protein binding of levofloxacin and moxifloxacin in patients with TB.
Topics: Humans; Levofloxacin; Moxifloxacin; Protein Binding; Tuberculosis | 2022 |
Antimicrobial Resistance of Helicobacter Pylori Among Low-resource Chinese Minorities.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Cross-Sectional Studies; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; East Asian People; Female; Gentamicins; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Moxifloxacin; Rifampin | 2023 |
[The problem of formation of new risks of medicinal resistance of patients with tuberculosis in condition of active use of antibiotics by population under COVID-19].
Topics: Anti-Infective Agents; Antitubercular Agents; Azithromycin; COVID-19; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mycobacterium tuberculosis; Pandemics; Quinolones; Tuberculosis | 2023 |
In-Class Cross-Reactivity among Hospitalized Patients with Hypersensitivity Reactions to Fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Hypersensitivity; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2023 |
The Formation and Drug Resistance Mechanism of Biofilm for Streptococcus pneumoniae Infection in Severe Respiratory Patients.
Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance; Drug Resistance, Bacterial; Erythromycin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae | 2023 |
Long-term Cardiovascular Adverse Events Induced by Fluoroquinolones: A Retrospective Case-control Study.
Topics: Case-Control Studies; Ciprofloxacin; Fluoroquinolones; Heart Valve Diseases; Humans; Levofloxacin; Moxifloxacin; Retrospective Studies | 2023 |
Protein binding investigation of first-line and second-line antituberculosis drugs.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein Binding; Pyrazinamide; Rifampin; Tuberculosis | 2023 |